| Date | Title | | | | 12/30/15 | HeartWare International Confirms Receipt Of Director Nominations Notice| -- Company Remains Committed to Value-Enhancing Acquisition of Valtech Cardio, Ltd. --
FRAMINGHAM, Mass., Dec. 30, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today confirmed that it has received a notice from Engaged Capital, LLC ("Engaged Capital") nominating three director candidates for election to HeartWare's Board ... |
| |  | | 12/17/15 | Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference| DUBLIN - Dec 17, 2015 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced it will participate in the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016, in San Francisco, California. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a formal presentation on the company beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 11, 2016,... |
|  | | | 12/16/15 | HeartWare Presentation At The J.P. Morgan Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Dec. 16, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:00 p.m. PT (5:00 p.m. ET). The conference is being held January 11-14 in... |
| | | | 12/14/15 | The Medtronic Bakken Invitation Award Honors 12 Patients from Around the World for Giving Back| Live On. Give On: Medtronic Philanthropy Provides MedTech Patients with $20,000 Grant to Direct to a Charitable Cause of Their Choice DUBLIN - December 14, 2015 - Medtronic (NYSE: MDT) announced today that 12 people representing 11 countries will be honored with the 2015 Bakken Invitation Award, which recognizes people who have overcome health challenges with the help of medical technology and are making outstanding contributions of service, volunteerism and leadership. From educating st... |
| | | | 12/14/15 | Medtronic Announces New High-Tech Facility in Galway; Building on Global Synergies| New facility to manufacture Medtronic's market- leading drug-coated balloons (DCB) technology DUBLIN- December 14, 2015 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, today announced a new manufacturing facility in Galway, Ireland that will manufacture the market-leading IN.PACT® Admiral® drug-coated balloon (DCB) for the treatment of peripheral artery disease (PAD). PAD is a build-up of plaque in arteries throughout the body leading to reduced blood... |
| | | | 12/11/15 | Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2016| DUBLIN - December 11, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2016 third quarter cash dividend of $0.38 per ordinary share, representing a 25 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June. Medtronic has increased its annual dividend payment for the past 38 consecutive years, and is a constituent of the S&P 500 Dividend Aristocrats index. The dividend is ... |
| | | | 12/11/15 | Medtronic Announces FDA Approval of Infuse® Bone Graft for Three New Spine Surgery Indications| Approval adds new implants and new surgical approaches to current spine labeling DUBLIN - December 11, 2015 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of additional spine surgery indications for Infuse® Bone Graft. Upon receiving final labeling approval from the FDA, the company expects to begin marketing these expanded indications in early calendar year 2016. With this expanded approval, Medtronic will be able to market Infuse Bone Graft for use... |
| | | | 12/11/15 | Medtronic and Samsung Expand Alliance to Develop Connected Health Solutions for Neuromodulation Patients and Healthcare Providers | DUBLIN - December 11, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Samsung Electronics America, a global leader in consumer electronics and digital health, today announced a broad-based strategic alliance to accelerate the development of digital health solutions for the millions of people suffering from chronic pain, movement disorders, incontinence, and other conditions who could benefit from neuromodulation therapy. People with these conditions, as well as thei... |
| | | | 12/09/15 | Medtronic Announces FDA Approval for the Only Full-Body MR Conditional Deep Brain Stimulation Systems| Updated Labeling Allows Greater Patient Access to MRI, a Critical Diagnostic Tool DUBLIN - December 9, 2015 - Medtronic plc (NYSE: MDT) today announced that systems within its Activa® portfolio of Deep Brain Stimulation (DBS) neurostimulators have received FDA approval for full-body Magnetic Resonance Imaging (MRI)* under specific conditions of use. Medtronic's MR Conditional DBS systems are the only approved for full-body MRI scans. This approval expands access to MRIs, making it safe for pati... |
| | | | 12/08/15 | University of Washington to Lead U.S. Expansion of Medtronic's HeartRescue Project| The Newly Formed U.S. HeartRescue Consortium Will Bring Proven Resuscitation Practices to More States to Improve Sudden Cardiac Arrest Survival Rates DUBLIN - December 8, 2015 - Medtronic (NYSE: MDT) today announced that the University of Washington and King County (Seattle) Emergency Medical Services will lead the U.S. expansion of the HeartRescue Project, a successful Medtronic Philanthropy partnership launched in five states in 2010 that brought together some of the nation's leading resuscita... |
| | | | 12/03/15 | Medtronic Reports Second Quarter Financial Results| Revenue of $7.1 Billion Grew 6% on a Comparable, Constant Currency Basis; 62% as Reported Non-GAAP Diluted EPS of $1.03; GAAP Diluted EPS of $0.36 Free Cash Flow of $1.1 Billion; GAAP Cash Flow from Operations of $1.3 Billion Company Updates Revenue Growth Outlook and FY16 EPS Guidance DUBLIN - December 3, 2015 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2016, which ended October 30, 2015. Unless otherwise noted, all revenue g... |
| | | | 12/02/15 | HeartWare Presentation At The Oppenheimer 26th Annual Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Dec. 2, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Oppenheimer 26th Annual Healthcare Conference on December 8, 2015 at 10:20 a.m. ET. The conference is being held December 8-9 in New York.
A live we... |
| | | | 12/02/15 | Medtronic Expands Access to Type 2 Diabetes Products with Selection of Henry Schein as Exclusive Distributor| New U.S. Distribution Agreement Extends Reach into Primary Care Physician Market DUBLIN and MELVILLE, N.Y. - December 2, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has selected Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc. (NASDAQ: HSIC), as an exclusive distributor of selected diabetes products to primary care physicians (PCPs) in the U.S. The exclusive distribution agreement broadens access to Medtronic solutions for people with type 2 di... |
| | | | 11/30/15 | Medtronic Enhances Utility of Professional Continuous Glucose Monitor (CGM) by Launching Pattern Snapshot for iPro®2 Professional CGM| Simplified Report Uses New Algorithms to Streamline Diabetes Data Interpretation for the Health Care Professional DUBLIN - November 30, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the availability of a new CareLink® iPro report called Pattern Snapshot for iPro2 Professional CGM system. The new one-page report provides a health care professional (HCP) with information for quick interpretation of detailed glucose data over time. The identified pattern... |
| | | | 11/24/15 | HeartWare Presentation At The Piper Jaffray 27th Annual Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Nov. 24, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Piper Jaffray 27th Annual Healthcare Conference on December 1, 2015 at 3:00 p.m. ET. The conference is being held December 1-2 in New York.
A live ... |
| | | | 11/20/15 | Medtronic Statement on U.S. Department of Treasury's Notice 2015-79| DUBLIN - Nov. 20, 2015 - Medtronic plc (NYSE:MDT) has conducted a preliminary review of the United States Department of Treasury's Notice 2015-79, issued on November 19, 2015, which is aimed at addressing certain aspects of transactions known as "tax inversions." Medtronic has concluded that the actions announced in Notice 2015-79 do not have a material financial impact on the company. Medtronic will continue to more fully assess Notice 2015-79 and will provide appropriate disclosur... |
| | | | 11/18/15 | Latest Cardiac and Diabetes Advancements from Medtronic Win 2015 'Best of What's New' Awards from Popular Science| World's Smallest Pacemaker and Investigational Insulin Pump System Recognized Among the Top 100 Technology Innovations DUBLIN - November 18, 2015 - Medtronic plc (NYSE: MDT) today announced that its Micra® Transcatheter Pacing System (TPS) and Hybrid Closed Loop system have both earned the 2015 'Best of What's New' award in the health category by Popular Science, the world's largest science and technology magazine. Selected after careful evaluation of thousands of submissions, the Micra TPS an... |
| | | | 11/18/15 | Medtronic Acquires Aircraft Medical to Aid in the Preventable Issue of Respiratory Compromise| Aircraft's Offering Allows Clinicians a Single, Hybrid Device for All Intubations DUBLIN - November 18, 2015 - In support of the company's therapy innovation strategy, Medtronic plc (NYSE:MDT) today announced it has acquired Aircraft Medical, a privately-held medical device company based in Edinburgh, Scotland, that develops affordable, handheld high-quality video laryngoscopes used by anesthesiologists and critical care professionals to intubate patients. The Aircraft Medical acquisition is an... |
| | | | 11/17/15 | Medtronic Announces FDA Approval and Launch of World's First App-Based Remote Monitoring System for Pacemakers| MyCareLink Smart(TM) Monitor Conveniently Connects Pacemaker Patients and Doctors System Compatible with Android(TM) and Apple® Smartphones and Tablets DUBLIN - Nov. 17, 2015 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial availability of the MyCareLink Smart(TM) Monitor, the world's first app-based remote monitoring system for patients with implantable pacemakers. With the MyCareLink Smart Monitor, patients with a Medtronic pa... |
| | | | 11/17/15 | Medtronic's Endurant AAA Stent Graft Delivers Durable, Consistent and Proven Outcomes at Four Years in Real-World Setting| Four-Year Subset Analysis from Global ENGAGE Registry Demonstrates Positive Outcomes in Challenging Anatomies DUBLIN and NEW YORK CITY- November 17, 2015 - Selected for nearly one of every two endovascular abdominal aortic aneurysm (AAA) repairs globally, the Endurant® AAA stent graft system from Medtronic plc (NYSE: MDT) continues to maintain durable and consistent outcomes at four years in real world settings, including challenging anatomies. Hence J.M. Verhagen, M.D., Ph.D., Professor and Ch... |
| | | | 11/16/15 | Medtronic Showcases Aortic Leadership in Innovation with Clinical Release and Pipeline at VEITH 2015| New Aortic Data Demonstrates Medtronic's Commitment to Innovation DUBLIN - November 16, 2015 - Medtronic plc (NYSE: MDT) today announced notable clinical studies and innovative technologies that will be presented at the annual VEITHsymposium, the world's premier conference for vascular surgeons specializing in the most current information and new developments in clinical practice and research. The conference is taking place in New York City from November 17-21, 2015. "Leveraging decades ... |
| | | | 11/12/15 | HeartWare Presentation At The Canaccord Genuity 2015 Medical Technology & Diagnostics Forum To Be Webcast| FRAMINGHAM, Mass., Nov. 12, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that HeartWare President and Chief Executive Officer, Doug Godshall, is scheduled to present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum on November 19, 2015 at 10:00 a.m. ET in New York.
A live webcast of t... |
| | | | 11/09/15 | World's Smallest Pacemaker, Medtronic Micra® TPS, Meets Global Clinical Trial's Safety and Effectiveness Endpoints| Data Presented at AHA and Simultaneously Published in the New England Journal of Medicine Demonstrate High Implant Success and Reduced Healthcare Utilization DUBLIN and ORLANDO - Nov. 9, 2015 - In the largest clinical data presentation ever of transcatheter pacing patients, Medtronic plc (NYSE: MDT) today announced that the Medtronic Micra® Transcatheter Pacing System (TPS) was successfully implanted in nearly all patients in the trial - 99.2 percent - and met its safety and effectiveness end... |
| | | | 11/09/15 | Medtronic Launches VenaSeal Closure System in the United States; Treats First Patient for Clinically Symptomatic Venous Reflux| New, Innovative Technology Brings Relief to Patients Suffering with Varicose Veins DUBLIN - November 9, 2015 - Medtronic plc (NYSE: MDT) today announced U.S. availability of the VenaSeal(TM) closure system, the first and only non-tumescent, non-thermal, non-sclerosant procedure approved for the treatment of symptomatic venous reflux in the U.S. The VenaSeal closure system was approved through the FDA's Pre-Market Approval (PMA) process, and is a minimally invasive procedure that uses a propriet... |
| | | | 11/06/15 | Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2016| DUBLIN - Nov. 6, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2016 on Thursday, December 3, 2015. A news release will be issued at approximately 5:45 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for the second fiscal quarter, which ended October 30, 2015. Medtronic will host a webcast at 7:00 a.m. Central Standa... |
| | | | 11/06/15 | HeartWare Presentation At The Credit Suisse 24th Annual Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Nov. 6, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that HeartWare President and Chief Executive Officer Doug Godshall is scheduled to present at the Credit Suisse 24th Annual Healthcare Conference on November 11, 2015 at 7:30 a.m. MT (9:30 a.m. ET). The conference is being held November 9-1... |
| | | | 11/05/15 | Medtronic Releases 2015 Integrated Performance Report| "Further, Together" Showcases the Company's Economic, Social and Environmental Performance in Fiscal Year 2015 DUBLIN - November 5, 2015 - Medtronic plc (NYSE:MDT) announces the release of its 2015 Integrated Performance Report, "Further, Together", which provides a compelling, comprehensive view of how Medtronic creates value over time through management of its financial resources, social investments, and environmental impacts. The report highlights the company's commitment... |
| | | | 11/03/15 | HeartWare International Announces Expiration Of Hart-Scott-Rodino Waiting Period In Connection With Acquisition Of Valtech Cardio| FRAMINGHAM, Mass., Nov. 3, 2015 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") for its acquisition of Valtech Cardio, Ltd. ("Valtech"), has expired.
The expiration of the HSR Act waiting period satisfies the cl... |
| | | | 11/02/15 | REALITY Study to Evaluate Use of Directional Atherectomy and Drug Coated Balloon in Patients with Peripheral Arterial Disease| VIVA Physician Sponsored Study to Determine the Benefits of Debulking Plaque and Maximizing Luminal Gain Prior to Drug Coated Balloon Therapy DUBLIN and LAS VEGAS - Nov. 2, 2015 - Medtronic plc (NYSE: MDT) announced today the initiation of the REALITY Study (DiRectional AthErectomy + Drug-coAted BaLloon to Treat Long, Calcified FemoropopliTeal ArterY Stenoses) to evaluate patient outcomes following adjunctive use of directional atherectomy and drug-coated balloon (DCB) treatment of patients wit... |
| | | | 11/02/15 | IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015| Health-Economic Analysis Demonstrates Medtronic IN.PACT Admiral Drug-Coated Balloon Is Cost-Effective Compared to Standard PTA; Global Study Data Demonstrates Strong Clinical Outcomes in Patients with In-Stent Restenosis DUBLIN and LAS VEGAS - Nov. 2, 2015 - Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB) with the presentation of both its formal cost-effectiveness analysis from the U.S. cohort of the IN.PACT SFA Trial and clinical results f... |
| | | | 11/02/15 | Medtronic Unveils New Aortic and Peripheral Data from Two Late-Breaking Clinical Trials at VIVA 2015| Meeting Highlights New Two-Year Data with Valiant Thoracic Stent Graft in Type B Aortic Dissection and Nine-Month Comparison Data in Leading Treatments for Peripheral Iliac Artery Disease DUBLIN and LAS VEGAS - Nov. 2, 2015 - Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015. Valiant Captiva Demonstrates Safety and Efficacy at Two Y... |
| | | | 10/29/15 | HeartWare International Reports Third Quarter 2015 Results| -- Total revenue of $65.2 million reflects completion of enrollment in destination therapy clinical trial and international currency weakness
-- International unit sales increased 18% from third quarter of 2014
-- 697 HeartWare HVAD® Systems sold worldwide
- Conference call today at 8:00 a.m. U.S. ET -
FRAMINGHAM, Mass., Oct. 29, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies tha... |
| | | | 10/29/15 | Medtronic and the World Stroke Organization Partner for the Second Year in Recognition of World Stroke Day| Former New York Giant Carl Banks Joins to Support Activities in New York City DUBLIN - October 29, 2015 - In recognition of World Stroke Day, Medtronic plc (NYSE: MDT) and the World Stroke Organization are joining together for the second year to raise awareness of stroke, which affects an estimated 15 million people worldwide each year. Together, Medtronic and the World Stroke Organization are encouraging people to take 2 minutes to learn about the signs of stroke and then tell 2 people about t... |
| | | | 10/28/15 | Cleveland Clinic Names Stent Retriever Technology One of the Top Medical Innovations for 2016| Medtronic Pioneered the First Stent Retriever in 2007 with the Introduction of the SolitaireTM Stent Retriever Device DUBLIN - October 28, 2015 - The Cleveland Clinic has named stent retriever technology, which includes Medtronic plc's (NYSE: MDT) SolitaireTM stent retriever device, to a list of the top medical innovations for 2016. The top medical innovations list was revealed today at the Cleveland Clinic's 2015 Medical Innovation Summit. This news comes months after the American Heart Assoc... |
| | | | 10/28/15 | HeartWare International Analyst And Investor Meeting On November 5, 2015 To Be Webcast| FRAMINGHAM, Mass., Oct. 28, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it will be hosting an analyst and investor meeting on November 5, 2015 from 9:00 a.m. ET until 1:00 p.m. ET. The meeting will be webcast live at http://ir.heartware.com, and a replay will be made available following conclus... |
| | | | 10/28/15 | Medtronic Focuses on a Preventable Patient Safety Issue: Respiratory Compromise| New Data Presented at ANESTHESIOLOGY® 2015 Demonstrates the Value of Integrated Pulmonary IndexTM and MicrostreamTM Capnography SAN DIEGO - October 28, 2015 - Medtronic plc (NYSE: MDT) today announced findings from two clinical studies, the first validating the clinical utility of the Integrated Pulmonary Index(TM) (IPI) in the post anesthesia care unit (PACU) to identify respiratory adverse events (RAE) and the second, a study on the cost-effectiveness of capnography in gastrointestinal (GI) s... |
| | | | 10/21/15 | Medtronic Commits $2 Million to Support Smithsonian's National Museum of African American History and Culture| Opening in 2016, the Museum Will Explore the African American Experience and How It Helped Shape American History and Culture. DUBLIN - Oct. 21, 2015 - Medtronic (NYSE: MDT) today announced that it will become a founding donor to the Smithsonian's National Museum of African American History and Culture, committing $2 million over five years from Medtronic Philanthropy. The new museum, the Smithsonian's 19th, will be the only national museum devoted exclusively to the documentation of African A... |
| | | | 10/21/15 | Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation| Diagnosing AF with Visia AF(TM) and Visia AF MRI(TM) SureScan® ICDs Enables Physicians to Manage Patients at Increased Risk for Stroke and Heart Failure DUBLIN - October 21, 2015 - Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Visia AF(TM) and Visia AF MRI(TM) SureScan® single-chamber implantable cardioverter defibrillators (ICDs), which can detect and monitor new onset, asymptomatic, and previously undiagnosed atrial fibrillation (AF). Early ... |
| | | | 10/20/15 | HeartWare Schedules Third Quarter 2015 Conference Call And Webcast| FRAMINGHAM, Mass., Oct. 20, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended September 30, 2015, at 8:00 a.m. U.S. ET on Thursday, October 29, 2015. The company plans to release the financial results prior to the conference call.
The conference call with management will discuss the company's financial results, highlights from the third quarter and business outlook. Th... |
| | | | 10/19/15 | Medtronic Partners with Local Organizations and Minnesota Department of Health to Advance Health Equity in Minnesota| Pillsbury United Communities, Regions Hospital Foundation, HealthFinders Collaborative Will Implement "HealthRise" in Minnesota, One of Four Projects in the World. MINNEAPOLIS - October 19, 2015 - Medtronic (NYSE: MDT) today announced that Pillsbury United Communities, Regions Hospital Foundation and the HealthFinders Collaborative have been selected by Medtronic Philanthropy to implement the HealthRise U.S. program in Minnesota. Additionally, Medtronic Philanthropy and the Minneso... |
| | | | 10/15/15 | Study Shows Prestige LP(TM) Cervical Disc Patients Maintained Improved Clinical Outcomes and Patient Satisfaction Compared to Fusion at Seven Years| DUBLIN and CHICAGO - October 15, 2015 - Medtronic plc (NYSE: MDT) today announced favorable seven-year data maintaining improved clinical outcomes and patient satisfaction for the Prestige LP(TM) Cervical Disc compared to anterior cervical discectomy and fusion (ACDF). The Prestige LP Disc - indicated for single-level cervical disc disease - is designed to preserve motion in the neck at the operated disc level, unlike a fusion surgery that does not allow for motion. The data, results of s... |
| | | | 10/14/15 | Medtronic Drug-Coated Balloon Sustains Superiority Over Balloon Angioplasty at Two Years in Patients with Peripheral Arterial Disease| Presented at TCT and Published in JACC, Two-Year Outcomes Reinforce IN.PACT Admiral's Durability, Consistency and Safety as a Best-in-Class Treatment Option for PAD DUBLIN and SAN FRANCISCO - October 14, 2015 - Medtronic plc (NYSE: MDT) announced today that new two-year clinical data from the pivotal IN.PACT SFA Trial revealed that the IN.PACT® Admiral® drug-coated balloon (DCB) continues to provide superior clinical outcomes at two years compared to standard balloon angioplasty for the interv... |
| | | | 10/14/15 | Medtronic CoreValve® Evolut® R System Demonstrates Exceptional Results at One Year| New Data Released at TCT 2015 Affirms Strong Performance of Recapturable and Repositionable Heart Valve Yielding Low Rates of Mortality and Stroke with Excellent Hemodynamics DUBLIN and SAN FRANCISCO - October 14, 2015 - Medtronic plc (NYSE: MDT) announced new one-year data showing transcatheter aortic valve replacement (TAVR) with the CoreValve® Evolut® R System-the first and only next-generation recapturable, self-expanding valve available in the U.S.-led to exceptional clinical outcomes. Pr... |
| | | | 10/13/15 | Medtronic CoreValve® System Shows Positive Clinical Outcomes in New Patient Populations| New Data Show Low Mortality and Improved Quality of Life for Patients with Failed Surgical Aortic Valves, End-Stage Renal Disease and Low Gradient Aortic Stenosis DUBLIN and SAN FRANCISCO - October 13, 2015 - Medtronic plc (NYSE: MDT) today unveiled new clinical data that showed positive clinical outcomes at one year for the CoreValve System in new patient populations with significant co-morbidities. Results from three patient populations evaluated within the CoreValve® U.S. Expanded Use Study ... |
| | | | 10/12/15 | Medtronic CoreValve® System Demonstrates Excellent Clinical Outcomes in First Report of 'Real-World' U.S. Experience| First Self-Expanding Valve Data from the STS/ACC TVT Registry Shows Outcomes in Everyday Clinical Practice at 30 Days are Consistent with the CoreValve U.S. Pivotal Trial DUBLIN and SAN FRANCISCO - October 12, 2015 - Medtronic plc (NYSE: MDT) today released the first CoreValve® Transcatheter Aortic Valve Replacement (TAVR) System outcomes data using CoreValve data from The Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry. The d... |
| | | | 10/12/15 | HBR, NEJM and Medtronic Launch New Initiative Driving Discussion on Value-Based Healthcare| Collaboration Between Harvard Business Review and The New England Journal of Medicine Sponsored by Medtronic DUBLIN - October 12, 2015 - As communities around the world increasingly adopt programs based on value-based healthcare principles, thought-leading perspectives on how to improve patient outcomes while addressing cost in the healthcare systems will be the focus of the new Harvard Business Review (HBR) Insight Center (https://hbr.org/insight-center/measuring-costs-and-outcomes-in-health-c... |
| | | | 10/12/15 | Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants| Presented for the First Time at TCT, Early Results from the RevElution Trial Demonstrate Early Vessel Healing and Controlled, Polymer-Free Drug Elution in Patients Treated with the Novel Next-Generation Stent DUBLIN and SAN FRANCISCO - Oct. 12, 2015 - Medtronic plc (NYSE: MDT) unveiled today new data from the first implants of its novel Drug-Filled Stent (DFS) at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The early results from an initial subset of patients in th... |
| | | | 10/09/15 | Medtronic Announces Updated Time of Day for Its 2015 Annual Meeting| DUBLIN - October 9, 2015 - Medtronic plc (NYSE: MDT) today announced that the start time of the company's 2015 annual general meeting of shareholders (the Annual Meeting) has been moved one hour earlier to 8:00 a.m. Irish Standard Time, on Friday, December 11, 2015. Neither the date nor the location of the Annual Meeting have changed. As previously announced, the Annual Meeting will take place at the Conrad Dublin Hotel, Earlsfort Terrace, Dublin 2, Ireland, and shareholders of record as of th... |
| | | | 10/08/15 | Medtronic TYRX(TM) Neuro Absorbable Antibacterial Envelope now Available for Use with Implantable Neurostimulators| DUBLIN - October 8, 2015 - Medtronic plc (NYSE: MDT) today announced the first implants of the TYRX(TM) Absorbable Antibacterial Envelope with Medtronic Deep Brain Stimulation (DBS) systems. The implants were conducted by Francisco Ponce, M.D., director, Barrow Center for Neuromodulation, at the Barrow Neurological Institute in Phoenix. Medtronic recently received FDA clearance for the TYRX Neuro Absorbable Antibacterial Envelope for use with implantable neurostimulators (INS), and the product i... |
| | | | 10/06/15 | Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015| Meeting Highlights New Two-Year Data on IN.PACT Admiral DCB, First Report of Real-World TVT Registry with CoreValve System, First One-Year Data on Recapturable Evolut R, and Initial Results on First Implants of Drug-Filled Stent
DUBLIN - October 6, 2015 - Medtronic plc (NYSE: MDT) today announced a preview of notable clinical studies that will be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) symposium, the world's largest educational meeting specializing in interventio... |
| | | | 10/05/15 | Medtronic's Valiant® Thoracic Stent Graft System Demonstrates Durability After Five Years| Valor II U.S. Study Shows Strong Safety and Efficacy in Treatment of Thoracic Aortic Aneurysms DUBLIN and Newport, R.I. - October 5, 2015 - Medtronic plc (NYSE:MDT) today announced favorable five-year data in the VALOR II Study, demonstrating the durability of the Valiant® Thoracic Stent Graft System, an innovative and minimally invasive treatment for patients with thoracic aortic aneurysms (TAA). The data, results of five-year patient follow-up, were presented on Friday, October 2, 2015 by Mar... |
| | | | 10/05/15 | HeartWare Issues Statement Regarding Engaged Capital Comments| - Engaged Capital Analysis Is Incomplete -
- HeartWare Reiterates Commitment to Value-Enhancing Acquisition of Valtech Cardio -
FRAMINGHAM, Mass., Oct. 5, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today issued the following statement in response to Engaged Capital's public comments regarding the Company's pending... |
| | | | 10/02/15 | Medtronic Completes Acquisition of Twelve, Inc.| DUBLIN - October 2, 2015 - Medtronic plc (NYSE: MDT) today announced that it has completed the acquisition of Twelve, Inc. ("Twelve"), a privately-held medical device company based in Redwood City, CA, focused on the development of a transcatheter mitral valve replacement (TMVR) device. "This acquisition supports Medtronic's therapy innovation strategy, as TMVR represents an important growth opportunity for our business," said Sean Salmon, senior vice president and presiden... |
| | | | 09/30/15 | FDA Approves Expanded Use of Innovative Trial System for Incontinence Therapy| Discreet, Wireless Touch-Screen System Allows for Shorter Evaluations Expediting the Potential for Long-Term Restoration of Bladder or Bowel Function DUBLIN - September 30, 2015 - The U.S. Food and Drug Administration (FDA) recently approved the use of the Verify(TM) Evaluation System for basic evaluations, which last 3-7 days, thereby expediting the potential for long-term restoration of bladder or bowel function. Before making a long-term commitment, the Verify System allows patients to test ... |
| | | | 09/29/15 | New Global Partnership, RHD Action, Calls on World Leaders to End Rheumatic Heart Disease | Preventable Condition Causes 275,000 Deaths Annually, Primarily Among Women, Children and Adolescents in Developing Countries New York - September 29, 2015 - RHD Action, a new global movement to end rheumatic heart disease (RHD), launched today on the occasion of the United Nations General Assembly in New York. Global health experts, healthcare providers, people living with RHD and others called for new action against this easily preventable but neglected disease, which is a major cause of se... |
| | | | 09/28/15 | Medtronic Acquires Lazarus Effect| Lazarus Effect's Innovative "Mesh Cover" Technology is Complementary to Medtronic's Solitaire(TM) Stent Retriever Platform DUBLIN - September 28, 2015 - Medtronic plc (NYSE:MDT) today announced it has acquired Lazarus Effect, a Campbell, Calif.-based and privately-held medical device company focused on acute ischemic stroke products that facilitate the capture and removal of clots. The acquisition is another example of the company's commitment to its key growth strategy of therapy i... |
| | | | 09/28/15 | MiniMed® Connect Now Available from Medtronic for Smartphone Access to Personal Diabetes Data| Medtronic Furthers Move toward Holistic Diabetes Management by Integrating Devices, Data and Consumer Technology DUBLIN - September 28, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. commercial availability of MiniMed Connect, the first and only product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitoring (CGM) information on a smartphone. MiniMed Connect provides greater conveni... |
| | | | 09/22/15 | Medtronic Initiates Global Study of Minimally Invasive Technology to Aid Lung Cancer Diagnosis| Demonstrating Commitment To Reduce Lung Cancer Morbidity, Study Will Enroll Up To 2,500 Patients Globally As the #1 Cancer Killer, Lung Cancer Deaths Surpass Breast, Colon and Prostate Cancer Combined DUBLIN - September 22, 2015 - Committed to reducing lung cancer morbidity around the world, Medtronic's (NYSE: MDT) Minimally Invasive Therapies Group recently launched a 2,500-patient, international study to assess real-world impact of its superDimension(TM) navigation system. The Company devel... |
| | | | 09/14/15 | Medtronic and Vikings Begin Multi-Year Community Sponsorship| 3-Acre Medtronic Plaza to Become Community Gathering Place and Provide Backdrop for Start of Medtronic TC Marathon and Medtronic TC 10 Mile MINNEAPOLIS - September 14, 2015 - Medtronic (NYSE: MDT) and the Minnesota Vikings today announced a 10-year partnership that includes the exclusive sponsorship of Medtronic Plaza, the three-acre gateway between downtown Minneapolis and U.S. Bank Stadium; a community service program with the Vikings; and a permanent display of the history of medical technol... |
| | | | 09/14/15 | Medtronic First to Receive FDA Approval for MR-Conditional Implantable Cardioverter Defibrillator System| Evera MRI ICD System Approved for Use During Full Body MRI Scans for Patients at Risk of Sudden Cardiac Arrest DUBLIN - Sept. 14, 2015 - Medtronic plc (NYSE: MDT) today announced that it has received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter defibrillator (ICD) system for use with magnetic resonance imaging (MRI) scans. The Medtronic Evera MRI(TM) SureScan® ICD System is approved for MRI scans on any part of the body without positioning rest... |
| | | | 09/14/15 | Medtronic EVP & CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference| DUBLIN - Sept. 14, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015, in New York. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic on Thursday, September 17, 2015, beginning at 12:55 p.m. EDT (11:55 a.m. CDT). A live audio webcast of the presentation will be available on Se... |
| | | | 09/10/15 | Medtronic Named a Leading Company For Sustainability| DUBLIN – September 10, 2015 –Medtronic plc (NYSE: MDT) was recognized as one of the world's leading companies for sustainability with its ranking on the Dow Jones Sustainability North America Index (DJSI North America) for the eighth consecutive year. DJSI North America analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship and social responsibility. This adds to the recognition Medtronic received earlier this year through it... |
| | | | 09/08/15 | Medtronic EVP & CFO Gary Ellis to Speak at Wells Fargo Healthcare Conference| DUBLIN - Sept. 8, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2015, in Boston. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic on Wednesday, September 9, 2015, beginning at 8:15 a.m. EDT (7:15 a.m. CDT). A live audio webcast of the presentation will be available on September 9, 2015, ... |
| | | | 09/03/15 | HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Sept. 3, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that its President and Chief Executive Officer, Doug Godshall, is scheduled to present at the 2015 Wells Fargo Healthcare Conference at 8:50 a.m. ET on Wednesday, Sept. 9, 2015. The conference is being held Sept. 9-10, 2015 at The Hyatt Reg... |
| | | | 09/03/15 | Medtronic Reports First Quarter Financial Results| Revenue of $7.3 Billion Grew 12% on a Comparable, Constant Currency Basis Including Extra Week Benefit; 70% as Reported Non-GAAP Diluted EPS of $1.02; GAAP Diluted EPS of $0.57 U.S. Revenue of $4.1 Billion Grew 14% on a Comparable Basis Including Extra Week Benefit; 78% as Reported Company Reiterates FY16 Revenue Growth Outlook and EPS Guidance DUBLIN - Sept. 3, 2015 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2016, which ended... |
| | | | 09/01/15 | HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd.| - Expands Position as a Leader in the Treatment of Heart Failure Patients -
- Adds Comprehensive Suite of Surgical and Transcatheter Mitral and Tricuspid Valve Repair and Replacement Technologies to the HeartWare Product Portfolio -
- Investor Conference Call on Sept. 1, 2015 at 5:00 p.m. U.S. EDT -
FRAMINGHAM, Mass. and OR YEHUDA, Israel, Sept. 1, 2015 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR), a leading innovator of less invasive, miniaturized circulatory sup... |
| | | | 09/01/15 | Medtronic, Inc. Announces Results of the Registered Exchange Offers for Certain of Its Senior Notes| DUBLIN - September 1, 2015 - Medtronic plc (the "Company") (NYSE: MDT) today announced the final results of its exchange offers (the "exchange offers") with respect to: (i) up to $500,000,000 aggregate principal amount of outstanding Floating Rate Senior Notes due March 15, 2020 issued by Medtronic, Inc. ("Medtronic, Inc."), together with the subsequent full and unconditional guarantees of such notes by the Company and Medtronic Global Holdings S.C.A. (&q... |
| | | | 08/31/15 | Medtronic Acquires Medina Medical| Medina Medical Breakthrough Aneurysm Embolization Mesh Technology Expands Hemorrhagic Stroke Portfolio DUBLIN-- August 31, 2015 -- Medtronic plc (NYSE:MDT) today announced it has acquired Medina Medical, a Menlo Park, Calif.-based and privately-held medical device company focused on commercializing state-of-the-art treatments for vascular abnormalities of the brain including cerebral aneurysms. This acquisition is another example of the company's commitment to its key growth strategy of therap... |
| | | | 08/31/15 | Medtronic Study Detects Gene Associated with Sudden Cardiac Death| First-of-its-Kind Discovery Furthers Understanding of Role of Genetics in Sudden Cardiac Death, May Help Identify Patients at Increased Risk DUBLIN and LONDON - August 31, 2015 - Medtronic plc (NYSE: MDT) today announced first-of-its-kind findings from two independent studies that have identified a gene associated with life-threatening abnormal heart rhythms. The study results were presented in a hotline session at the 2015 European Society of Cardiology (ESC) Congress in London. The studies e... |
| | | | 08/25/15 | Medtronic to Acquire Twelve, Inc., Developer of Transcatheter Mitral Valve Replacement Device| DUBLIN - August 25, 2015 - In support of the company's therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. ("Twelve"), a privately-held medical device company based in Redwood City, Calif., focused on the development of a transcatheter mitral valve replacement (TMVR) device. Twelve is the twelfth company spun out from the premier medical device incubator The Foundry. "Upon close, this acquisitio... |
| | | | 08/21/15 | Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2016| DUBLIN - August 21, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2016 second quarter cash dividend of $0.38 per ordinary share, representing a 25 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June. Medtronic has increased its annual dividend payment for the past 38 consecutive years, and is a constituent of the S&P 500 Dividend Aristocrats index. The dividend is p... |
| | | | 08/20/15 | Medtronic Announces 2015 Global Heroes Team, Marking 10 Years of the Program and 234 Runners Honored| Distance Runners from Six Continents Benefitting from Medical Technology to Run Medtronic Twin Cities Marathon Events this October MINNEAPOLIS - August 20, 2015 - Twenty-five long-distance runners who benefit from medical technology will be honored as the 2015 "Medtronic Global Heroes" when they run as a team in the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile on Sunday, October 4, 2015. This year's team includes runners from six continents and 16 different countries: Bra... |
| | | | 08/20/15 | Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2016| DUBLIN - August 20, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2016 on Thursday, September 3, 2015. A news release will be issued at approximately 6:15 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for the first fiscal quarter, which ended July 31, 2015. Medtronic will host a webcast at 7:00 a.m. Central Dayligh... |
| | | | 08/14/15 | Medtronic Supports Boston Area Retreat & Refresh Stroke Camp for Stroke Survivors and Caregivers| Brigham and Women's Hospital, Massachusetts General Hospital and Spaulding Rehabilitation Hospital Bring Stroke Camp to Area Stroke Survivors and Caregivers DUBLIN - August 14, 2015 - Three leading Boston-area hospitals - Brigham and Women's Hospital, Massachusetts General Hospital and Spaulding Rehabilitation Hospital - have teamed up to bring stroke victims the Retreat & Refresh Stroke Camp (Stroke Camp), sponsored by Medtronic. Stroke Camp, a three-day retreat for stroke survivors, caregive... |
| | | | 08/10/15 | HeartWare Completes Enrollment In ENDURANCE2 Supplemental Destination Therapy Trial| - ENDURANCE2 is the Largest Destination Therapy Clinical Trial of a Ventricular Assist Device Conducted to Date -
FRAMINGHAM, Mass., Aug. 10, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been completed. ENDURANCE2 is the largest dest... |
| | | | 08/05/15 | Medtronic Launches the Entrust(TM) Delivery System in the United States| New System Provides an Easy to Use, Accurate and Controlled, One-Handed Stent Delivery System When Treating Patients with Peripheral Arterial Disease DUBLIN - August 5, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of its Entrust(TM) delivery system in the United States. The new Entrust delivery system enables physicians to place Medtronic's EverFlex(TM) self-expanding peripheral stent, while maintaining a low profile and providing the ease of a one-handed device. "The Entru... |
| | | | 08/04/15 | Medtronic, Inc. Commences Registered Exchange Offer for Certain of its Senior Notes| DUBLIN - August 4, 2015 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of exchange offers (the "exchange offers") with respect to: (i) up to $500,000,000 aggregate principal amount of outstanding Floating Rate Senior Notes due March 15, 2020 issued by Medtronic, Inc. ("Medtronic, Inc."), together with the subsequent full and unconditional guarantees of such notes by the Company and Medtronic Global Holdings S.C.A. ("Medtronic Luxco... |
| | | | 08/04/15 | HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast| FRAMINGHAM, Mass., Aug. 4, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that its President and Chief Executive Officer, Doug Godshall, is scheduled to present at the Canaccord Genuity 35th Annual Growth Conference at 8:30 a.m. EDT on Thursday, August 13, 2015. The conference is being held August 12-13, 2015 at ... |
| | | | 08/03/15 | CMS Grants New Technology Add-On Payment for Inpatient Use of Medtronic's Drug-Coated Balloon| Decision Will Provide Patients with Additional Access to New Medical Device with Potential to Improve Standard of Care for Peripheral Arterial Disease in Vessels Above the Knee DUBLIN -- August 3, 2015 -- Medtronic plc (NYSE: MDT) announced today that the U.S. Centers for Medicare and Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for the company's IN.PACT® Admiral® drug-coated balloon (DCB) under the Medicare hospital inpatient prospective payment system (IPPS). The... |
| | | | 07/30/15 | Medtronic Supports First Retreat & Refresh Stroke Camp for Stroke Survivors and Caregivers Held in Minnesota| Stroke Survivors and Caregivers Relax, Unwind and Recharge in Supportive Environment with the Help of Abbott Northwestern Hospital DUBLIN - July 30, 2015 - Medtronic will sponsor Minnesota's first Retreat & Refresh Stroke Camp (Stroke Camp), a three-day retreat for stroke survivors, caregivers and family members being held Aug. 7-9, 2015 in Ironwood Springs, Minnesota, in association with Abbott Northwestern Hospital, part of Allina Health. This is the second of four rehabilitative camps sponso... |
| | | | 07/30/15 | HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth| - Record 773 HeartWare HVAD® Systems sold worldwide in second quarter, with record unit sales in both U.S. and international markets
- U.S. revenue grew 16% to $42.9 million, compared to second quarter 2014
- International revenue of $30.7 million, an increase of 10% from second quarter 2014 on a constant-currency basis
-- Conference call today at 8:00 a.m. U.S. EDT --
FRAMINGHAM, Mass., July 30, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator... |
| | | | 07/21/15 | HeartWare Schedules Second Quarter 2015 Conference Call And Webcast| FRAMINGHAM, Mass., July 21, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended June 30, 2015, at 8:00 a.m. U.S. ET on Thursday, July 30, 2015. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the second quarter and business outlook. The call may be accessed b... |
| | | | 07/20/15 | HeartWare International Announces First Human Implants Of The MVAD® System In CE Mark International Clinical Trial| - The MVAD System is a versatile, miniaturized and hematologically advanced circulatory assist system designed for full-support of patients with advanced heart failure -
FRAMINGHAM, Mass., July 20, 2015 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced commencement of its MVAD® System CE Mark international clinical ... |
| | | | 07/15/15 | Tissue is the Issue When Performing a Biopsy for Potential Lung Cancer| -Company Launches GenCut(TM) Core Biopsy System for Minimally Invasive Use with the superDimension(TM) Navigation System for Lung Tissue Biopsies- -Multiple Lung Core Tissue Samples Now Possible with a Single Pass- DUBLIN - July 15, 2015 - Medtronic (NYSE:MDT) now offers the GenCut(TM) core biopsy system, a unique lung tissue biopsy tool for use with the superDimension(TM) navigation system. The superDimension(TM) system enables a minimally invasive approach to accessing difficult-to-reach are... |
| | | | 07/13/15 | Medtronic to Acquire RF Surgical Systems, Developer of Detection System for the Prevention of Retained Surgical Sponges| Technology Designed to Prevent Surgical-Related "Never Events" DUBLIN-- July 13, 2015 -- Medtronic plc (NYSE:MDT) today announced it has signed a definitive agreement to acquire RF Surgical Systems, Inc., a medical device company based in Carlsbad, Calif., focused on the detection and prevention of retained surgical items (sponge, gauze or towel) for approximately $235 million. Additional terms of the acquisition were not disclosed. Despite rigorous surgical sponge counting protocol... |
| | | | 07/08/15 | Medtronic Awards $1.1 Million in Twin Cities Health Access Grants| Medtronic Philanthropy Grants Support 22 Local Organizations Committed to Expanding Access to Healthcare for the Underserved Minneapolis - July 8, 2015 - Medtronic Philanthropy has recently awarded $1.1 million in Health Access Grants to 22 Minnesota-based nonprofit organizations, supporting each to expand healthcare services in underserved communities across the metropolitan area, with an emphasis on such chronic conditions as heart disease and diabetes. Each organization listed below will rec... |
| | | | 07/08/15 | Medtronic Announces the Global Launch of the CD Horizon® Solera® Voyager (TM) Spinal System| DUBLIN - July 8, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of the CD HORIZON® SOLERA® VOYAGER(TM) Spinal System for Minimally Invasive Spine procedures. Available today in countries around the world, the CD HORIZON® SOLERA® VOYAGER(TM) System expands upon the transforaminal lumbar interbody fusion (TLIF) procedure by offering multiple, minimally invasive rod insertion options and enabling a seamless 3D-navigated surgical experience. The announcement was made during t... |
| | | | 07/02/15 | Data Demonstrates Durability of Medtronic's VenaSeal Closure System, a Non-Tumescent, Non-Thermal and Non-Sclerosant Procedure for Chronic Venous Insufficiency| 12 month closure rates for the VenaSeal closure system comparable to radiofrequency ablation DUBLIN -- July 2, 2015 -- Medtronic plc (NYSE: MDT) today announced the twelve-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system for the treatment of incompetent greater saphenous veins with a 96.8 percent closure rate. The results were presented by National Principal Investigator, Nick Morrison, M.D., Morrison Vein Institute... |
| | | | 06/30/15 | Medtronic Announces Date for 2015 Annual Meeting| Annual Meeting to be held in Dublin, Ireland on December 11, 2015 DUBLIN - June 30, 2015 - The board of directors of Medtronic plc (NYSE: MDT) announced that the company's annual meeting of shareholders will be held at 9:00 a.m. Irish Standard Time, on Friday, December 11, 2015 at the Conrad Hotel, Earlsfort Terrace, Dublin, Ireland. Shareholders of record at the close of business on October 12, 2015, will be eligible to vote at the meeting. The 2015 Annual Meeting will be the first to be held... |
| | | | 06/29/15 | American Heart Association's New Stroke Treatment Guidelines Establish Stent Retrievers as First-Line Endovascular Treatment for Acute Ischemic Stroke| DUBLIN - June 29, 2015 - Today, the American Heart Association/American Stroke Association (AHA/ASA) published new stroke treatment guidelines that recommend the use of stent retriever technology - such as Medtronic plc's (NYSE: MDT) SolitaireTM stent retriever device - in conjunction with the current standard of care, IV-tPA, as a first-line treatment for eligible patients. The guidelines are based on a panel of experts' analysis of the results from five global clinical trials published in The ... |
| | | | 06/25/15 | Medtronic Announces Expansion of MR-Conditional Products with U.S. Launch of Advisa SR MRI(TM) SureScan® Pacing System| Single-Chamber Pacemaker Allows for Full-Body MRI Scans Without Positioning Restrictions DUBLIN- June 25, 2015 - Medtronic plc (NYSE: MDT), today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of the Advisa SR MRI(TM) SureScan® single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging (MRI) scans positioned on any region of the body without restrictions. The new system includes the Advisa SR MRI pacemaker and a SureScan le... |
| | | | 06/25/15 | Medtronic Names Geoff Martha Executive Vice President and President, Restorative Therapies Group| Martha Succeeds Christopher J. O'Connell; Bill Burke Named Medtronic Chief Integration Officer DUBLIN - June 25, 2015 - Medtronic plc (NYSE: MDT) announced today that it has named Geoff Martha as executive vice president and president, Medtronic Restorative Therapies Group (RTG), effective immediately. Martha will replace Christopher J. O'Connell, who was selected to become chief executive officer of a public company. "Chris has passionately served Medtronic for the past 21 years ... |
| | | | 06/24/15 | World's Smallest Pacemaker, Medtronic Micra TPS, Wins Top European Innovation Award for 2015| Award Follows Late-breaking Presentation Showing Medtronic Micra Transcatheter Pacemaker Meets Initial Safety and Performance Measures DUBLIN and MILAN - June 24, 2015 - Medtronic plc (NYSE: MDT) today announced that its Micra® Transcatheter Pacing System (TPS) has won the top innovation award for practice improvement at EHRA EUROPACE-CARDIOSTIM 2015 in Milan. The award is selected by an international panel of experts, scientists and physicians who review the competing products and choose the ... |
| | | | 06/23/15 | Medtronic Implements Worldwide Voluntary Recall for Certain Lots of Neonatal and Pediatric Tracheostomy Tubes| DUBLIN - June 23, 2015 - Medtronic (NYSE: MDT) announced that on May 8, 2015, it began notifying hospitals and distributors worldwide that affected lots of its Covidien Shiley(TM) tracheostomy tubes were formed with a wider-angle bend than standard models manufactured after November 29, 2012. The company initiated the field action following a small number of customer complaints that included reports of 12 serious patient injuries, such as breathing difficulties that impacted oxygen levels immed... |
| | | | 06/23/15 | Medtronic Announces FDA Approval for New TAVR System, Introduces First and Only Recapturable Heart Valve in U.S.| CoreValve® Evolut(TM) R Recapturable and Repositionable Heart Valve Improves Positioning Accuracy and Control During Deployment DUBLIN - June 23, 2015 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the new recapturable, self-expanding CoreValve® Evolut(TM) R System. The first-and-only recapturable and repositionable device available in the U.S., the Evolut R System is approved for transcatheter aortic valve replacement (TAVR) ... |
| | | | 06/22/15 | Medtronic Calls for Applications for 2015 Bakken Invitation Award| Ten Honorees Will Each Earn a $20,000 Grant DUBLIN - June 22, 2015 - Medtronic plc (NYSE: MDT) announced today that it is seeking applications for the 2015 Bakken Invitation Award, a global program honoring and connecting people who have overcome health challenges with the help of medical technology and are now selflessly giving back to their communities. Currently in its third year, the Bakken Invitation Award will honor ten inspirational people who use their "extra life" - gained ... |
| | | | 06/22/15 | World's Smallest Pacemaker, Medtronic Micra TPS, Featured in Late-Breaking Trial Session at EUROPACE 2015| Global clinical trial finds Medtronic Micra Transcatheter Pacemaker Meets Initial Safety and Performance Measures DUBLIN and MILAN - June 22, 2015 - Medtronic plc (NYSE: MDT) today reported study results of its Micra® Transcatheter Pacing System (TPS) at a late-breaking clinical trials session at EHRA EUROPACE-CARDIOSTIM 2015 in Milan. The study results demonstrated that the miniaturized pacemaker met initial safety and performance measures in its global clinical trial. Of the first 140 patie... |
| | | | 06/20/15 | Endurant AAA Stent Graft Maintains Durable, Consistent and Proven Outcomes for Abdominal Aortic Aneurysm Repair in Long-Term Follow-Up| Five-Year Results from U.S. IDE Study Presented at Society for Vascular Surgery Meeting CHICAGO - June 20, 2015 - Selected for nearly one of every two endovascular abdominal aortic aneurysm (AAA) repairs globally, the Endurant AAA stent graft system from Medtronic plc (NYSE: MDT) maintained durable, consistent and proven outcomes through five years of follow-up in the company's U.S. clinical study of the implantable medical device, according to new clinical data presented today at the Society f... |
| | | | 06/19/15 | Medtronic Acquires Aptus Endosystems| Aptus Endosystems' Helical Anchor Technology Complements Medtronic's Aortic Stent Platform for the Treatment of Complex Aortic Disease DUBLIN-- June 19, 2015 -- Medtronic plc (NYSE:MDT) today announced it has acquired the assets of Aptus Endosystems, Inc., a Sunnyvale, Calif. based, privately held medical device company focused on developing advanced technology for endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR). Medtronic completed its acquisition of the... |
| | | | 06/19/15 | Medtronic Announces Acquisition of CardioInsight Technologies, Developer of Non-Invasive Cardiac Mapping System| DUBLIN - June 19, 2015 - Medtronic plc (NYSE: MDT) today announced that it has acquired CardioInsight Technologies, Inc. ("CardioInsight"), a privately-held, Cleveland-based medical device company that has developed a new approach to improve the mapping of electrical disorders of the heart. CardioInsight will become part of the Medtronic Atrial Fibrillation Solutions business in the Cardiac Rhythm and Heart Failure division. Medtronic completed its acquisition of CardioInsight on a deb... |
| | | | 06/19/15 | Medtronic Increases Cash Dividend by 25 Percent| Dividend Payout Ratio Now Approximately 35%; Targeting 40% Dividend Payout Ratio Within Next Few Years DUBLIN - June 19, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved a 25 percent increase in its cash dividend for fiscal year 2016, raising the quarterly amount to $0.38 per ordinary share for an annual amount of $1.52 per ordinary share. Today's announcement marks the 38th consecutive year of an increase in the dividend payment for Medtronic, a constituent of the S&P ... |
| | | | 06/17/15 | Medtronic announces financial investment in Arsenal AAA, LLC | DUBLIN -- June 17, 2015 -- Medtronic plc (NYSE:MDT) today announced a financial investment in Arsenal AAA, LLC ("Arsenal AAA"), a wholly owned subsidiary of Arsenal Medical, Inc. ("Arsenal Medical"). In return, Medtronic received an option to acquire Arsenal AAA after the company achieves certain milestones. Financial terms of the investment were not disclosed. Arsenal AAA is developing a proprietary foam and delivery mechanism designed to fill the aneurysmal sac around an en... |
| | | | 06/10/15 | Medtronic Initiates U.S. Launch of Fortrex(TM) PTA Balloon | The Fortrex PTA Balloon Provides High Pressure Solution to Maintain Arteriovenous Access DUBLIN -- June 10, 2015 -- Medtronic plc (NYSE: MDT) announced today the launch of the Fortrex(TM) over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. The Fortrex PTA balloon catheter utilizes a high pressure balloon to break up the blockages and open the vessels to help maintain arteriovenous (AV) access in the peripheral vascular system. "Being able to maintain AV acce... |
| | | | 06/09/15 | New Bariatric Surgery Device from Medtronic Makes the Most Common Weight Loss Procedure in U.S. More Consistent and Efficient| GastriSail(TM) Gastric Positioning System Combines Benefits of Three Devices Into One DUBLIN - June 9, 2015 - Furthering its commitment to fight obesity with innovative bariatric surgical solutions, Medtronic (NYSE:MDT) now offers the GastriSail(TM) gastric positioning system to help promote more consistent sleeve creation1 and greater procedural efficiency1 within the sleeve gastrectomy procedure, the most commonly performed weight loss procedure in the U.S.2 Developed by Medtronic's Minimal... |
| | | | 06/08/15 | HeartWare International Issues Voluntary Device Correction| - Information Provided to Reinforce Performance and Safe Use of the HeartWare® Ventricular Assist System -
FRAMINGHAM, Mass., June 8, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR) issued a voluntary Urgent Medical Device Correction on May 11, 2015, describing five different types of complaints reviewed as part of HeartWare's ongoing product performance monitoring. The notice provides information to reinforce proper performance and safe use of the HeartWare® Ventricular A... |
| | | | 06/08/15 | BD and Medtronic Collaborate to Introduce a New Infusion Set with BD FlowSmart(TM) Technology Designed to Improve Insulin Pump Therapy| New Innovation Demonstrates Reductions in Flow Interruptions, Including Silent Occlusions BOSTON, MA - JUNE 8, 2015 - BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Medtronic (NYSE: MDT) today announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart(TM) technology. An insulin infusion set delivers insulin from the pump to the body and is a critical part of the overall pump system. As part of ... |
| | | | 06/06/15 | Medtronic Accelerates Path to Artificial Pancreas with New MiniMed 640G Data and Start of Hybrid Closed Loop Trial| MiniMed 640G System Shown to Further Reduce Hypoglycemia; Pivotal Study to Examine Safety of Hybrid Closed Loop System for People with Diabetes BOSTON - June 6, 2015 - As part of its commitment to developing an artificial pancreas for people with diabetes, Medtronic plc (NYSE:MDT) today announced results from the European User Evaluation of the MiniMed® 640G system, which demonstrated that the pump's exclusive SmartGuard technology can reduce hypoglycemia (low blood glucose) and offer further ... |
| | | | 06/05/15 | Medtronic and Samsung Partner to Enhance Diabetes Management and Empower Overall Patient Health| BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Samsung Electronics, a world leader in consumer electronics committed to transformative mobile health and wellness solutions, today announced a partnership to improve diabetes management for the millions of people at risk and currently living with the disease. People with diabetes want convenient access to effectively manage their health from anywhere and at any time. Medtronic and Samsung Electr... |
| | | | 06/05/15 | Medtronic Receives FDA Clearance of MiniMed® Connect for More Convenient Access to Personal Diabetes Data | People with Diabetes and Their Loved Ones Will Have Smartphone Access to Diabetes Information; Healthcare Teams Have More Convenient Data Access with Daily Uploads BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed® Connect. Designed to provide a mobile connection to critical information for managing diabetes, MiniMed Connect is the first product to enable people with diabetes t... |
| | | | 06/05/15 | Medtronic Expands Access to Diabetes Device Data Through Agreement with Glooko | Medtronic Aims to Provide People with Diabetes, Their Care Teams and Healthcare Providers with Greater Insights to Improve Care BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an agreement with Glooko, the trusted leader in diabetes data unification and analytics, to improve access to meaningful diabetes health data in a safe and secure way. The partnership will incorporate information from Medtronic insulin pumps and continuous glucose... |
| | | | 06/04/15 | Medtronic CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference| DUBLIN - June 4, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 36th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 10, 2015, in Rancho Palos Verdes, CA. Omar Ishrak, chairman and chief executive officer of Medtronic, will answer questions about the company beginning at 8:00 a.m. PDT (10:00 a.m. CDT). A live audio session of the presentation will be available on June 10, 2015, by clicking on th... |
| | | | 06/04/15 | HeartWare Presentation At The Goldman Sachs 36th Annual Global Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., June 4, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that its presentation at the Goldman Sachs 36th Annual Global Healthcare Conference will be webcast live on Thursday, June 11, 2015 at 8:00 a.m. PDT (11:00 a.m. EDT). The conference is being held June 9-11 at Terranea in Rancho Palos Verde... |
| | | | 06/02/15 | Medtronic Reports Fourth Quarter and Fiscal Year 2015 Financial Results| Q4 Worldwide Revenue of $7.3 Billion Grew 7% on a Comparable, Constant Currency Basis; 60% as Reported Q4 Non-GAAP Diluted EPS of $1.16; GAAP EPS were Break-even Q4 U.S. Revenue of $4.1 Billion Grew 8% on a Comparable Basis; 67% as Reported FY15 Revenue of $20.3 Billion Grew 19% as Reported, or 6% on a Comparable, Constant Currency Basis Q4 Free Cash Flow of $1.7 Billion; GAAP Cash Flow from Operations of $1.9 Billion Company Sets Initial FY16 Revenue Growth Outlook and EPS Guidance ... |
| | | | 05/21/15 | Medtronic CEO Omar Ishrak to Speak at Sanford Bernstein Strategic Decisions Conference| DUBLIN - May 21, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Sanford Bernstein 31st Annual Strategic Decisions Conference on Friday, May 29, 2015, in New York. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about Medtronic beginning at 11:00 a.m. EDT (10:00 a.m. CDT). A live audio webcast of the presentation will be available on May 29, 2015, by clicking on the Investors ... |
| | | | 05/20/15 | Medtronic Drug-Coated Balloon for Treatment of Peripheral Arterial Disease Shows Strong Results in Long Lesions| First Report of Findings from IN.PACT Global Study's Imaging Cohort Presented at EuroPCR PARIS -- May 20, 2015 -- Presented for the first time today at EuroPCR during the "Hot line" session on "Peripheral interventions," new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic plc (NYSE: MDT) successfully treated long lesions in the superficial femoral and popliteal arteries. Prof. Dierk Scheinert, chairman of the divisio... |
| | | | 05/19/15 | Medtronic Announces Preliminary Fourth Quarter and Fiscal Year 2015 Revenue Results| Preliminary Q4 Worldwide Revenue of Approximately $7.3 Billion Grew 7% on a Comparable, Constant Currency Basis; 60% as Reported Preliminary Q4 U.S. Revenue of Approximately $4.1 Billion Grew 8% on a Comparable Basis; 67% as Reported Preliminary FY15 GAAP Revenue of Approximately $20.3 Billion Grew 19% as Reported, or 6% on a Comparable, Constant Currency Basis Company Tightens Fourth Quarter Adjusted EPS Expectations DUBLIN - May 19, 2015 - Medtronic plc (NYSE: MDT) today ann... |
| | | | 05/18/15 | New resources help healthcare providers understand, diagnose mystery strokes| DALLAS - May 18, 2015 - A new guide helps healthcare professionals better understand and diagnose strokes of unknown cause. The free resource is part of an American Heart Association/American Stroke Association initiative in collaboration with Medtronic plc (NYSE: MDT) which aims to reduce the rate of recurrent strokes in the U.S. Every year, nearly 800,000 Americans have a stroke, the fifth leading cause of death and a primary cause of disability. The most common type of stroke, called "... |
| | | | 05/18/15 | Data Show Medtronic Quadripolar CRT Technology Optimizes Treatment for Heart Failure Patients| Positive Results from Two Studies Featured at Heart Rhythm Society 36th Annual Scientific Sessions DUBLIN and BOSTON - MAY 18, 2015 -Medtronic plc (NYSE: MDT) today announced study results demonstrating that its quadripolar cardiac resynchronization therapy (CRT) system gives physicians more options to optimize CRT delivery, which may improve heart failure patients' response to the therapy. During Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston, data fro... |
| | | | 05/15/15 | Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device Infection Rates at 12 Months| Long-term Citadel/Centurion Clinical Trial Findings and Independent Data Presented at Heart Rhythm Society 36th Annual Scientific Sessions DUBLIN and BOSTON - MAY 15, 2015 - Medtronic plc (NYSE: MDT) today announced that its TYRX(TM) Antibacterial Envelope reduces major cardiac device site infections by 80 percent, up to 12 months after implantation. These data were presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston. The Citadel/Centurion Clini... |
| | | | 05/15/15 | Global Clinical Trial Finds Medtronic Micra® Transcatheter Pacemaker Meets Initial Safety and Performance Measures| Initial Safety and Performance Data of World's Smallest Pacemaker Featured in Late-Breaking Session at Heart Rhythm 2015 DUBLIN and BOSTON - May 15, 2015 - Medtronic plc (NYSE: MDT) today announced study results of its Micra® Transcatheter Pacing System (TPS), which demonstrated that the miniaturized pacemaker has met its initial safety and performance measures. In the largest report to date of a transcatheter pacing system, 100 percent of the first 140 patients who received the Micra TPS exper... |
| | | | 05/14/15 | Global Trial Finds Medtronic Micra® Transcatheter Pacemaker Meets Initial Safety Measures in Wide Range of Patients| Initial Safety Data on World's Smallest Pacemaker Presented at Heart Rhythm 2015 DUBLIN and BOSTON - May 14, 2015 - Medtronic plc (NYSE: MDT) revealed today the first safety data on its Micra® Transcatheter Pacing System (TPS). In the largest reported sample of a transcatheter pacing system to date, the first 140 patients in the Medtronic Micra TPS Global Clinical Trial showed 100 percent were successfully implanted with the Micra TPS. The data were presented at Heart Rhythm 2015, the Heart Rh... |
| | | | 05/14/15 | Medtronic Evera MRI ICD Clinical Study Meets Safety and Efficacy Endpoints| Late-Breaking Session at Heart Rhythm 2015 Features World's First Randomized Study of an MRI-Conditional Implantable Cardioverter Defibrillator Undergoing Full-Body MRI Scans; Study Simultaneously Published in JACC DUBLIN and BOSTON - May 14, 2015 - Medtronic plc (NYSE: MDT) today announced clinical trial results for the Medtronic Evera MRI(TM) SureScan® implantable cardioverter defibrillator (ICD) following MRI scans. The study showed that full-body magnetic resonance imaging (MRI) scans do no... |
| | | | 05/14/15 | Medtronic Responds to Nepal Earthquake| More than $1 Million Given in Financial Aid, Product Donations, Employee Contributions DUBLIN - May 14, 2015 - Medtronic plc (NYSE: MDT) announced today that it has pledged $100,000 to the American Red Cross to support earthquake relief efforts in Nepal, bringing the company's total current response to more than $1 million in cash and products. The $100,000 directed to the American Red Cross will help it support the Nepal Red Cross in recovery efforts and provide basic needs for injured and ... |
| | | | 05/12/15 | Medtronic Reiterates Announcement Timing of Its Fourth Quarter and Fiscal Year 2015 Financial Results| Preliminary Revenue Results to be Issued on May 19 Financial Results to be Issued and Webcast to be Held on June 2 DUBLIN - May 12, 2015 - Medtronic plc (NYSE: MDT) reiterated today that on Tuesday, May 19, 2015, it will announce preliminary financial results for the fourth quarter and fiscal year 2015, which ended April 24, 2015. A news release will be issued on May 19, 2015, at approximately 7:30 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com. The new... |
| | | | 05/12/15 | Medtronic Receives FDA Approval and CE Mark for Arctic Front Advance® ST Cryoballoon to Treat Atrial Fibrillation| Third-Generation Cryoballoon Designed to Allow Enhanced Positioning and Help Improve Capture of Real-Time Data with Achieve® Mapping Catheter DUBLIN - May 12, 2015 - Medtronic plc (NYSE: MDT) today announced the Arctic Front Advance® ST Cryoablation Catheter has received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation. In Europe, where the Cryoballoon has a broader indication, Arctic Front... |
| | | | 05/07/15 | HeartWare Announces Private Placement Of $148 Million Of 1.75% Convertible Senior Notes Due 2021| - Exchanged $79 Million of 1.75% Convertible Senior Notes due 2021 for 3.50% Convertible Senior Notes due 2017
- Raised an additional $69 Million of 1.75% Convertible Senior Notes due 2021
FRAMINGHAM, Mass., May 7, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), announced today that it has entered into privately-negotiated, exchange and subscription agreements with a limited number of holders of the Company's outstanding 3.50% Convertible Senior Notes due 2017 ("2017 No... |
| | | | 05/07/15 | Medtronic Initiates Study of 'In-Office' Insertion of Reveal LINQ(TM) Cardiac Monitor| RIO 2 Study Evaluates Safety and Effectiveness of Moving the Insertion Procedure from Hospital to Office Setting DUBLIN - May 7, 2015 - Medtronic plc (NYSE: MDT) today announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal LINQ In-Office 2 (RIO 2) Study. The world's smallest cardiac monitor was successfully implanted in an office setting at Scripps Clinic in La Jolla, California, by cardiologist John Rogers, M.D. The RIO 2 study will determine... |
| | | | 05/06/15 | Medtronic to Unveil First-of-Its-Kind Clinical Data for Cardiac Therapies at Heart Rhythm 2015| Late-Breaking Clinical Trial Sessions Feature First Data on Evera MRI® ICD and Micra® TPS DUBLIN - May 6, 2015 - Medtronic plc (NYSE: MDT) today announced its schedule of notable clinical studies that will be presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston, including two late-breaking clinical trials featuring the Evera MRI® SureScan® implantable cardioverter-defibrillator (ICD) System and Micra® Transcatheter Pacing System (TPS). Results ... |
| | | | 05/05/15 | Medtronic Announces FDA Clearance and U.S. Launch of the Euphora(TM) Semicompliant Coronary Balloon| Company to Launch "Cath Lab Connect" Informational Portal and Community Website for Cath Lab Professionals DUBLIN - May 5, 2015 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the Euphora(TM) Semicompliant Balloon Dilatation Catheter, a pre-dilatation therapy used during a stent implantation to reopen a narrowed coronary artery caused by plaque buildup. The first patient case with the Euphora Semicompliant Ba... |
| | | | 05/04/15 | Medtronic Announces Launch of DIVERGENCE(TM) Stand Alone Interbody Cage| DUBLIN - May 4, 2015 - Medtronic plc (NYSE: MDT), today announced the launch of the DIVERGENCE(TM) Stand Alone Interbody Cage. This device is now commercially available for the treatment of anterior cervical interbody fusion procedures in skeletally mature patients with cervical disc disease at one level from the C2-C3 disc to the C7-T1 disc. The announcement was made during the 83rd annual meeting of the American Association of Neurological Surgeons (AANS) in Washington, DC. The DIVERGENCE(TM)... |
| | | | 05/04/15 | HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast| FRAMINGHAM, Mass., May 4, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and CEO, Doug Godshall, is scheduled to present at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas on Thursday, May 14, 2015, at 10:00 a.m. PT (1:00 p.m. ET).
The live webcast of the Company's pre... |
| | | | 05/04/15 | Medtronic Receives FDA Clearance for ZEVO(TM) Anterior Cervical Plate System| DUBLIN - May 4, 2015 -Medtronic plc (NYSE: MDT) announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the ZEVO(TM) Anterior Cervical Plate System. This system is now commercially available for the treatment of cervical degenerative disc disease, trauma, tumors, deformity, pseudoarthrosis, and/or failed previous fusions. The ZEVO System represents Medtronic's latest technology for anterior cervical discectomy with fusion (ACDF) procedures. It featu... |
| | | | 05/04/15 | Medtronic Neurosurgery Receives Expanded Indications for the StealthStation® Electromagnetic Surgical Navigation Technology| Catheter and Electrode Placement Now FDA-cleared for Adult and Pediatric Patient Procedures DUBLIN - May 4, 2015 - Medtronic plc (NYSE: MDT) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded indications of specific StealthStation® electromagnetic (EM) surgical navigation system instruments for pediatric and adult cranial and ENT procedures. The clearance for these StealthStation electromagnetic instruments enables additional neurosurgi... |
| | | | 04/30/15 | Medtronic Initiates Study Evaluating Potential of Combination of Pulmonary Vein Isolation and Renal Denervation for Atrial Fibrillation| Enrollment Underway in the U.S. for Groundbreaking Study Involving Three Medtronic Devices: Arctic Front Advance(TM) Cryoballoon, Symplicity Spyral(TM) & Reveal LINQ(TM) ICM DUBLIN - April 30, 2015 - Medtronic plc (NYSE: MDT) today announced the start of a clinical study using Medtronic technologies to determine whether paroxysmal and persistent atrial fibrillation (AF) can be treated with a combination of two ablation procedures targeting different anatomical locations - specifically, the pul... |
| | | | 04/30/15 | HeartWare International Reports $70.0 Million In First Quarter 2015 Revenue| - 713 HeartWare® Systems sold worldwide in the first quarter of 2015
- U.S. revenue increased 25% over first quarter of 2014 to $42.2 million
- International revenue of $27.8 million; reflects unfavorable currency trends
- Next-generation MVAD® System targeted for first clinical use in Q2 2015
-- Conference call today at 8:00 a.m. U.S. ET --
FRAMINGHAM, Mass., April 30, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, minia... |
| | | | 04/29/15 | Endurant AAA Stent Graft System from Medtronic Delivers Consistently Strong Results in Abdominal Aortic Aneurysms with Short and Standard 'Neck' Lengths| Analysis of ENGAGE Registry Patients Presented at Charing Cross International Symposium LONDON -- April 29, 2015 -- For endovascular repair of abdominal aortic aneurysms, the Endurant(TM) AAA stent graft system from Medtronic plc (NYSE: MDT) delivered consistently strong results in patients with short and standard neck lengths who were enrolled in the global ENGAGE registry -- the largest contemporary database on the performance of a single company's stent grafts in real-world clinical practice... |
| | | | 04/27/15 | Medtronic Announces Consent Decree with FDA for the Synchromed Drug Infusion System and the Neuromodulation Quality System| Agreement Provides a Path to Resolution with Continued Patient Access DUBLIN - April 27, 2015 - Medtronic plc (NYSE: MDT) announced today that it has reached agreement on the terms of a consent decree with the U.S. Food and Drug Administration (FDA) specific to the company's SynchroMed® drug infusion system and the Neuromodulation quality system. The agreement is subject to approval by the U.S. District Court for the District of Minnesota. Medtronic will be contacting physicians to ensure they ... |
| | | | 04/27/15 | Medtronic Starts Clinical Study of Endurant Evo AAA Stent Graft System for Endovascular Treatment of Abdominal Aortic Aneurysms| Principal Investigators Perform First Implant of Investigational Medical Device Designed to Expand Applicability of Minimally Invasive Alternative to Open Surgical Repair DUBLIN -- April 27, 2015 -- Medtronic plc (NYSE: MDT) recently began a clinical study to evaluate the safety and effectiveness of the Endurant Evo AAA stent graft system, an investigational medical device designed to expand the applicability of a minimally invasive alternative to open surgical repair for the treatment of abdom... |
| | | | 04/22/15 | HeartWare Schedules First Quarter 2015 Conference Call And Webcast| FRAMINGHAM, Mass., April 22, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2015, at 8:00 a.m. U.S. ET on Thursday, April 30, 2015. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the first quarter and business outlook. The call may be accessed... |
| | | | 04/22/15 | Medtronic Announces European Approval of the First and Only Full-Body MR Conditional Deep Brain Stimulation Systems| Updated Labelling Allows Greater Patient Access to MRI DUBLIN - April 22, 2015 - Medtronic plc (NYSE: MDT) today announced that systems within its Activa® portfolio of Deep Brain Stimulation (DBS) Therapy neurostimulators have received European regulatory approval for MR Conditional full-body Magnetic Resonance Imaging (MRI).[*] The expanded approval for full-body MRI scans applies to all patients receiving a new system and to an estimated 13,000 people in Europe already receiving Medtronic DBS... |
| | | | 04/21/15 | Medtronic Begins Enrollment in Feasibility Study of Valiant 'Mona LSA' Branch Thoracic Stent Graft System | Investigational Device Enables Endovascular Repair of Aortic Aneurysms Encroaching on Left Subclavian Artery DUBLIN -- April 21, 2015 -- Medtronic plc (NYSE: MDT) today announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery (LSA). Cleveland Clinic cardio... |
| | | | 04/20/15 | Contemporary Results From Commercial HVAD® System Registries Highlighted At ISHLT Meeting In Nice, France| Data presented from Post-Approval INTERMACS Registry, ReVOLVE Long-Term Registry, European Retrospective Multi-Center Registry, and Mechanical Circulatory Support Research Network Registry
FRAMINGHAM, Mass., April 20, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today commented on results from multi-center commercial HVAD... |
| | | | 04/17/15 | Global Trials Show Addition of Medtronic's Solitaire Device Stent Thrombectomy Procedure in Treatment of Acute Ischemic Stroke Improves Neurological Outcomes| SWIFT PRIME and REVASCAT Confirm Findings of EXTEND-IA, ESCAPE and MR CLEAN, Support Addition of Solitaire Stent Thrombectomy to Current Standard of Care DUBLIN - April 17, 2015 - Two global trials published online in The New England Journal of Medicine (NEJM) and presented at the European Stroke Organisation Conference found that the addition of the Solitaire(TM) device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering strok... |
| | | | 04/16/15 | HeartWare Achieves Primary Endpoint In The ENDURANCE Destination Therapy Clinical Trial| Investigators Report Data from First Cohort in Destination Therapy at the 35th Annual International Society for Heart and Lung Transplantation Meeting in Nice, France
- Investor Breakout Session and Clinician Symposium to be Webcast Today -
FRAMINGHAM, Mass. and NICE, France, April 16, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced hea... |
| | | | 04/14/15 | Medtronic to Develop Stent Graft System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms Under Exclusive Patent License Agreement with Sanford Health| Collaboration Aims to Expand Treatment Options and Improve Outcomes for Patients DUBLIN, Ireland and SIOUX FALLS, S.D. -- April 14, 2015 -- The global leader in medical technology for endovascular aortic repair (EVAR), Medtronic plc (NYSE: MDT) today announced that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with South Dakota-based Sanford Health. A concept for the novel system, which wa... |
| | | | 04/14/15 | Medtronic Announces CE Mark of World's Smallest Pacemaker, Micra Transcatheter Pacing System| Miniaturized Device Less Than One-tenth the Size of a Conventional Pacemaker and Placed Directly in the Heart DUBLIN - April 14, 2015 - Medtronic plc (NYSE: MDT)today announced it has received CE (Conformité Européenne) Mark of the Micra® Transcatheter Pacing System (TPS), the world's smallest pacemaker. At less than one-tenth the size of traditional pacemakers, the Micra device provides the most advanced pacing technology available while being cosmetically invisible and small enough to be deli... |
| | | | 04/13/15 | IBM and Medtronic to Partner to Improve Diabetes Care| ARMONK, NY and DUBLIN - April 13, 2015 - IBM (NYSE: IBM) and Medtronic (NYSE: MDT) today announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit. With diabetes device data continuously gathered an... |
| | | | 04/10/15 | HeartWare Announces Webcasts At The 35th International Society for Heart and Lung Transplantation Annual Meeting| - Clinician Lunch Symposium and Investor Breakout Session to be Webcast -
FRAMINGHAM, Mass., April 10, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced it will webcast two events at the 35th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions in Nice, France ... |
| | | | 04/09/15 | Medtronic Initiates U.S. Launch of HawkOne(tm) Directional Atherectomy System for Treatment of Peripheral Arterial Disease| Third-Generation System Treats All Plaque Morphologies Including Severe Calcium, While Streamlining Procedural Efficiency DUBLIN -- April 9, 2015 -- Medtronic plc (NYSE: MDT) enhances its leading directional atherectomy portfolio with the U.S. launch of the HawkOne(TM) directional atherectomy system. The HawkOne system provides physicians with a solution to treat all plaque morphologies in patients with peripheral arterial disease, including patients who have plaque blockages that have become se... |
| | | | 04/09/15 | HeartWare International Receives Health Canada Approval For Commercialization Of The HeartWare® Ventricular Assist System As A Bridge To Heart Transplantation| - First, full-support, miniaturized ventricular assist device designed to be placed in the pericardial space to receive approval in Canada -
FRAMINGHAM, Mass., April 9, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from Health Canada, the country's federal department responsibl... |
| | | | 04/07/15 | GOLD AF Registry to Capture Real-World Insights Using Medtronic Phased RF Ablation to Treat Patients with Atrial Fibrillation| DUBLIN - April 7, 2015 - Medtronic plc (NYSE: MDT) today announced the first patient enrollment in the GOLD AF Registry, a first-of-its-kind, prospective, observational clinical study of its Phased Radiofrequency (RF) Ablation technology for treating patients with symptomatic atrial fibrillation (AF). The multicenter registry will provide real-world insights into the procedural use and treatment outcomes of the Pulmonary Vein Ablation Catheter® (PVAC) GOLD, multi-electrode ablation catheter and ... |
| | | | 04/02/15 | Medtronic Acquires Diabeter, Innovative Diabetes Care Provider| DUBLIN - April 2, 2015 - Medtronic plc (NYSE:MDT) today announced its acquisition of Diabeter, an innovative, independent Netherlands-based diabetes clinic and research center dedicated to providing comprehensive and individualized care for children and young adults with diabetes. Together, Medtronic and Diabeter will further develop and expand Diabeter's model of care so more people with diabetes can enjoy greater freedom and better health. This acquisition combines the strengths of Medtronic a... |
| | | | 04/01/15 | EverFlex(TM) Peripheral Stent from Medtronic Delivers Sustained Patency in Long, Complex Lesions| Three-Year Data from DURABILITY II Study Published inCatheterization and Cardiovascular Intervention Journal DUBLIN -- April 1, 2015 -- The EverFlex(TM) self-expanding peripheral stent system from Medtronic plc (NYSE: MDT) has proven to provide sustained patency in the treatment of long, complex lesions in the superficial femoral (SFA) and popliteal arteries, according to the three-year results of the DURABILITY II study, which are reported in the recent issue of Catheterization and Cardiova... |
| | | | 04/01/15 | Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation| DUBLIN - April 1, 2015 - Medtronic plc (NYSE:MDT) today announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a unique, phased clinical program studying renal denervation in uncontrolled hypertension. This announcement follows investigational device exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The program will begin with two global studies designed to address the confounding factors encountered in the SYMPLICITY HTN-3 clinical trial, including medi... |
| | | | 03/31/15 | Medtronic CoreValve® System Receives FDA Approval for Transcatheter Valve-In-Valve Procedures| First TAVR Device Indicated for Replacement of Failed Surgical Heart Valves Expands Patient Population That Can Benefit from Minimally Invasive Procedure DUBLIN - March 31, 2015 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the CoreValve® System for valve-in-valve (VIV) procedures in patients whose surgical aortic heart valves have failed. The CoreValve System is the first transcatheter heart valve approved in the U.S. for VIV procedu... |
| | | | 03/30/15 | Medtronic Announces Japanese Regulatory Approval of CoreValve® System| DUBLIN - March 30, 2015 - Medtronic plc (NYSE: MDT) today announced Japanese regulatory approval for the self-expanding transcatheter CoreValve® System for patients with severe aortic stenosis (AS) unable to undergo surgery, and for whom treatment with the CoreValve is determined to be the best option. Japanese regulatory authorities granted approval of the CoreValve system for transcatheter aortic valve implantation (TAVI) based on robust data from the CoreValve U.S. Pivotal Trials and the Medt... |
| | | | 03/26/15 | Medtronic Completes Acquisition of Sophono, Inc., Minimally Invasive Bone Conduction Hearing Implant Technology| Acquisition Expands Medtronic's ENT Portfolio with Innovative Hearing Restoration Therapy DUBLIN - March 26, 2015 - Medtronic plc (NYSE: MDT) announced today that it has completed the acquisition of Sophono, Inc., a privately held developer and manufacturer of innovative magnetic hearing implants in Boulder, Colorado. This acquisition enables Medtronic's Ear Nose and Throat (ENT) business to continue its focus on novel therapies and innovative technology solutions and supports Medtronic's thera... |
| | | | 03/25/15 | Medtronic Highlights New Data in JAMA Surgery Demonstrating Significant Cost Savings and Reduced Patient Hospital Stays Following Minimally Invasive Surgery| Study Shows Patients Who Underwent Laparoscopic Colon Resections Left Hospital Faster, Required Significantly Less Follow Up Care and Fewer Medicines Than Patients Who Underwent Open Surgery DUBLIN - March 25, 2015 - Adding to the clinical benefits and improved patient outcomes associated with minimally-invasive surgery (MIS), Medtronic plc (NYSE: MDT) today highlighted new data demonstrating that patients who underwent minimally invasive colon resection procedures were able to leave the hospit... |
| | | | 03/18/15 | Protégé GPS Self-Expanding Peripheral Stent System Receives FDA Approval for Use in Treating Iliac Artery Stenosis| DUBLIN -- March 18, 2015 -- Medtronic plc (NYSE: MDT) today announced that its Protégé(TM) GPS(TM) self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of stenotic lesions of the common and external iliac arteries. The news follows the nine-month results of the DURABILITY Iliac study, which were presented at the 2014 VIVA conference in Las Vegas. The results demonstrated the safety and effectiveness of the Protégé GPS ... |
| | | | 03/16/15 | Medtronic Seeks Runners with Medical Technology for 2015 "Global Heroes" Team| APPLICATIONS NOW OPEN: Selected Runners Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October DUBLIN - March 16, 2015 - Medtronic announced today that applications are open to runners around the world who benefit from medical technology to represent their country on the tenth Medtronic Global Heroes team. All runners with eligible medical devices are welcome to apply, regardless of device manufacturer. In nine years, 209 runners representing 28 dif... |
| | | | 03/15/15 | Medtronic CoreValve® System Sustains Superior Survival Benefit Over Open Heart Surgery at Two Years | Investigators Conclude that Results Presented as ACC.15 Late-Breaking Clinical Trial Suggest that Self-Expanding TAVR Should be Considered New Standard of Care DUBLIN and SAN DIEGO - March 15, 2015 - Medtronic plc (NYSE: MDT) today unveiled new, highly anticipated two-year data from the High Risk Study of the CoreValve U.S. Pivotal Trial, which continued to show superior survival benefit at two years for transcatheter aortic valve replacement (TAVR) with the CoreValve® System compared to patient... |
| | | | 03/14/15 | Medtronic to Initiate Clinical Study of Drug-Filled Stent Following Successful Preclinical Results| Novel Platform Enables Controlled, Polymer-Free Drug Elution, Designed to Help Address Next-Generation Technology Challenges DUBLIN and SAN DIEGO - March 14, 2015 - Advancing its interventional coronary portfolio with breakthrough engineering concepts in device design and technology, Medtronic plc (NYSE: MDT) unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed contro... |
| | | | 03/14/15 | Medtronic CoreValve® Evolut(TM) R System Yields Exceptional Outcomes in First Clinical Study| No Mortality or Stroke at 30-days and Excellent Procedural Results with Next-Generation Recapturable Valve DUBLIN and SAN DIEGO - March 14, 2015 - Medtronic plc (NYSE: MDT) today announced initial clinical outcomes for its next-generation CoreValve® Evolut(TM) R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six center... |
| | | | 03/12/15 | Medtronic Initiates Pivotal Studies of Resolute Onyx(TM) Drug-Eluting Stent in United States| Next-Generation Device with CoreWire Technology to be Studied in Wide Spectrum of Patients, Including the Smallest Coronary Arteries DUBLIN - March 12, 2015 - Medtronic plc (NYSE: MDT) today announced the start of its Resolute Onyx(TM) Clinical Program in the United States, which will evaluate the Resolute Onyx(TM) drug-eluting stent (DES) in patients who have coronary artery disease. Included in the first phase of the study are patients with small vessels that would require a 2.0 mm stent, wh... |
| | | | 03/04/15 | HeartWare Presentation At The 2015 Barclays Global Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., March 4, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2015 Barclays Global Healthcare Conference at 8:00 a.m. Eastern Time on Tuesday, March 10, 2015. The conference is being held March 10-12 at the Loews Miami Beach Hotel in Florida.
A... |
| | | | 03/03/15 | Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare Conference| DUBLIN - Mar 3, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference in Miami. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic on Wednesday, March 11, 2015, beginning at 9:30a.m. EDT (8:30a.m. CDT). A live audio webcast of the presentation will be available on March 11, 2015, by clicking on the Investors link on t... |
| | | | 02/27/15 | Medtronic EVP & President Michael J. Coyle to Speak at Cowen Healthcare Conference| DUBLIN - Feb 27, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Cowen and Company 35th Annual Healthcare Conference in Boston. Michael J. Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will make a presentation about Medtronic on Tuesday, March 3, 2015, beginning at 11:20 a.m. EST (10:20 a.m. CST). A live audio webcast of the presentation will be available on March 3, 2015, b... |
| | | | 02/27/15 | Medtronic Announces Irish High Court Approval of Share Premium Reduction| DUBLIN - February 27, 2015 -Medtronic plc (NYSE:MDT) today announced that the Irish High Court has approved the company's share premium reduction petition, creating the distributable reserves needed to support share repurchases or redemptions and payment of the cash dividend of $0.305 per ordinary share that was previously announced on February 13, 2015. The dividend remains payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend re... |
| | | | 02/26/15 | HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013| - U.S. revenue of $41.5 million, up 60% and International revenue of $31.7 million, up 17%, compared to fourth quarter of 2013
- Revenue for 2014 increased 34% to $278.4 million, from $207.9 million in 2013
- Conference call today at 8:00 a.m. U.S. ET -
FRAMINGHAM, Mass., Feb. 26, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart... |
| | | | 02/25/15 | HeartWare Presentation At The Raymond James 36th Annual Institutional Investors Conference To Be Webcast| FRAMINGHAM, Mass., Feb. 25, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 36th Annual Institutional Investors Conference on Tuesday, March 3, 2015 at 4:35 p.m. ET. The conference is being held March 1-4, at the JW Marriott Orlando Grande Lakes i... |
| | | | 02/24/15 | FDA Approves the VenaSeal(TM) Closure System for Treatment of Clinically Symptomatic Venous Reflux| VenaSeal Closure System, a Next-Generation Chronic Venous Insufficiency Procedure with Demonstrated Safety and Effectiveness DUBLIN - Feb. 24, 2015 - Medtronic plc today announced U.S. Food and Drug Administration approval for VenaSeal(TM) closure system, a minimally invasive procedure that uses a specially formulated medical adhesive to close lower superficial extremities such as the great saphenous vein in patients with symptomatic venous reflux. Venous reflux disease, also known as chro... |
| | | | 02/23/15 | Medtronic Acquires Advanced Uro-Solutions| NURO Percutaneous Tibial Nerve Stimulation System to Enhance Neuromodulation Product Offerings for Treatment of Bladder Control Issues DUBLIN - Feb. 23, 2015 - Medtronic plc (NYSE: MDT) today announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed. Advanced Uro-Solutions develop... |
| | | | 02/20/15 | HeartWare International Recalls Certain Older HeartWare® Clinical Trial Controllers| FRAMINGHAM, Mass., Feb. 20, 2015 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR), is issuing a voluntary Urgent Medical Device Recall in the United States related to older HeartWare® Ventricular Assist System Controllers, which were distributed in the U.S. during the clinical trial period prior to Food and Drug Administration (FDA) approval in 2012. HeartWare has commenced this field action in other countries in recent weeks. In letters to clinicians and patients, the company advi... |
| | | | 02/19/15 | Study Shows Medtronic Deep Brain Stimulation Therapy for Treatment-Resistant Epilepsy Demonstrates Significant and Sustained Seizure Reduction at Five Years| Results Also Show Sustained Safety, Intervals of Seizure Freedom, Improvements in Quality of Life and Reduction in Seizure Severity DUBLIN - February 19, 2015 - Medtronic plc (NYSE: MDT) today announced five-year results from the pivotal SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial, the largest clinical study of deep brain stimulation (DBS) therapy for epilepsy in adults with treatment-resistant (refractory) epilepsy characterized by partial-onset seizures. The ... |
| | | | 02/19/15 | Medicare Approves Transitional Pass-Through Payment for Outpatient Use of Medtronic Drug-Coated Balloon| CMS Decision Provides Supplemental Reimbursement to U.S. Hospitals for New Medical Device with Potential to Improve Standard of Care for Peripheral Arterial Disease in Upper Leg DUBLIN - Feb. 19, 2015 - Medtronic plc (NYSE: MDT) announced today that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for the company's IN.PACT Admiral drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system (OPPS), removing... |
| | | | 02/18/15 | Medtronic Leads Progress Toward an Artificial Pancreas for People with Diabetes| New Data on Future Medtronic Systems and Available MiniMed 640G System Accelerate Progress PARIS - February 18, 2015 - Medtronic plc (NYSE:MDT) is advancing the development and commercialization of artificial pancreas technology with new research demonstrating progress toward future innovations and new systems coming to market. The first clinical study results on Medtronic's Hybrid Closed Loop system will be presented at the upcoming Advanced Technologies and Treatments for Diabetes (ATTD) 8th... |
| | | | 02/17/15 | Medtronic Reports Third Quarter Earnings| Revenue of $4.3 Billion Grew 8% at Constant Currency, 4% as Reported Non-GAAP Diluted EPS of $1.01 Grew 11%; GAAP Diluted EPS of $0.98 Grew 31% U.S. Revenue Grew 8% on Strength of New Products Free Cash Flow of $1.7 Billion; GAAP Cash Flow from Operations of $1.8 Billion Company Completes Acquisition of Covidien at Beginning of Fourth Quarter; Integration Activities Underway DUBLIN - Feb. 17, 2015 - Medtronic plc (NYSE: MDT) today announced financial results for Medtronic, Inc.'s third... |
| | | | 02/16/15 | Medtronic Receives Expanded Indications of the VERTEX® Reconstruction System| Now FDA Cleared for Lateral Mass and Pedicle Screw Fixation in the Posterior Cervical Spine DUBLIN - Feb. 16, 2015 - Medtronic plc (NYSE: MDT), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded indications of the VERTEX® Reconstruction System. The new clearance for the VERTEX® family of products allows for lateral mass and pedicle screws to be used as a form of fixation to treat various pathologies occurring in the posterior... |
| | | | 02/16/15 | Medtronic Announces CE Mark and European Launch of the Euphora(TM) Semicompliant Coronary Balloon Catheter| Semicompliant Balloon Brings Greater Deliverability to Combat Challenging Coronary Lesions DUBLIN - February 16, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of the Euphora(TM) Semicompliant Balloon Dilatation Catheter in countries that recognize the CE (Conformité Européene) mark. The first patient case with the Euphora Semicompliant Balloon Catheter was recently performed by Richard Edwards, M.D., consultant cardiologist at the Freeman Hospital in Newcastle, United Kingdom. It ... |
| | | | 02/13/15 | HeartWare Schedules Fourth Quarter Conference Call And Webcast| FRAMINGHAM, Mass., Feb. 13, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, February 26, 2015. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the fourth quarter and business outlook. ... |
| | | | 02/13/15 | The American Heart Association - American Stroke Association and Medtronic Collaborate to Reduce Recurrent Strokes| A Leading Cause of Disability and Death, Many Strokes Have No Known Cause DUBLIN and NASHVILLE, TENN. - Feb. 13, 2015 - The American Heart Association/American Stroke Association (AHA/ASA) and Medtronic plc (NYSE: MDT), today announced a collaboration to reduce the rate of recurrent strokes in the U.S. The two organizations will work together over several years to educate, raise awareness and support effective management of patients who have strokes, one of the most devastating diseases affecti... |
| | | | 02/13/15 | Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2015| DUBLIN - February 13, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved a cash dividend of $0.305 per ordinary share, conditioned on receipt of Irish Court administrative approval expected to be received by early March 2015. The dividend is payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend represents a 9% increase over the prior year. Medtronic, a constituent of the S&P 500 Dividend Aristocrats index, ha... |
| | | | 02/12/15 | FDA Classifies Previous Covidien Field Action for Its Trellis-6(TM) and Trellis-8(TM) Peripheral Infusion Systems As a Class 1 Recall| DUBLIN - February 12, 2015 - Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6(TM) and Trellis-8(TM) peripheral infusion systems has now been classified as a Class 1 Recall by the U.S. Food and Drug Administration. Customers were previously notified by Covidien of the recall on December 15, 2014. The company has not received any reports of patient injuries related to this issue. If a patient has received treat... |
| | | | 02/12/15 | Study Analyzes Real-World Use of Medtronic's MiniMed 530G System| Diabetes Technology & Therapeutics Publishes Retrospective Analysis Detailing Impact of Threshold Suspend in Addressing Hypoglycemia DUBLIN - February 12, 2015 - Medtronic plc (NYSE:MDT) today announced results of a retrospective analysis based on real-world data from over 20,000 MiniMed® 530G users, which found that the pump's Threshold Suspend feature reduced hypoglycemia, especially at night, without significantly increasing hyperglycemia. The results, titled "Retrospective Analysis of ... |
| | | | 02/11/15 | Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2015| DUBLIN - Feb 11, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for Medtronic, Inc.'s third quarter of its fiscal year 2015 on Tuesday, February 17, 2015. A news release will be issued at approximately 6:15 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic Inc.'s third fiscal quarter, which ended January 23, 2015. Medtronic will host a webcast at... |
| | | | 02/11/15 | Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies| ESCAPE and EXTEND-IA Show Improved Neurological Outcomes with Addition of Stent Thrombectomy
DUBLIN - February 11, 2015 - Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire(TM) Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke.
Both the EXtending the Time for Thrombo... |
| | | | 02/11/15 | Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients in 'Real-World' Study| Findings Reinforce Patient Benefit of Reveal LINQ in Real-World Setting New Data Demonstrate Cost-Effectiveness of Long-Term, Continuous Cardiac Monitoring with Potential to Prevent Recurrent Strokes DUBLIN and NASHVILLE - Feb. 11, 2015 - Medtronic plc (NYSE: MDT), today announced the results of a new "real-world" study of patients who have had a cryptogenic stroke (stroke of unknown cause), in which the Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) detected atrial fibrillation i... |
| | | | 02/10/15 | British Journal of Surgery Publishes Five-Year ClosureFast(TM) Study Results| Results Demonstrate Durability, Effectiveness of Treatment for Chronic Venous Insufficiency DUBLIN - Feb. 10, 2015 - The ClosureFast(TM) endovenous radiofrequency ablation catheter from Medtronic plc (NYSE: MDT) is safe and effective for the treatment of chronic venous insufficiency (CVI) over five years, according to data published in the February 2015 issue of British Journal of Surgery. The five-year results of the ClosureFast Long-Term European Multi-Center Study demonstrate the durabilit... |
| | | | 02/05/15 | HeartWare Presentation At The 2015 Leerink Global Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Feb. 5, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2015 Leerink Global Healthcare Conference at 10:20 a.m. EST on Thursday, February 12, 2015. The conference is being held February 11-12 at the Waldorf Astoria in New York City.
A live... |
| | | | 02/05/15 | Medtronic's Pipeline(TM) Flex Embolization Device Receives FDA Approval| Minimally-Invasive Flow Diversion Device for Unruptured Brain Aneurysms Designed for More Exact and Controlled Placement1 DUBLIN - February 5, 2015 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Pipeline(TM) Flex embolization device. Available through a limited U.S. launch in the coming weeks, Medtronic's latest-generation flow diversion device represents an... |
| | | | 02/04/15 | Medtronic Starts U.S. Launch of IN.PACT Admiral Drug-Coated Balloon for Treatment of Peripheral Arterial Disease in Upper Leg| First Uses of New Medical Device Following FDA Approval Take Place at Hospitals Nationwide DUBLIN - Feb. 4, 2015 - U.S. hospitals this week began using a new medical device from Medtronic plc (NYSE: MDT) called the IN.PACT Admiral drug-coated balloon (DCB) to treat patients with peripheral arterial disease (PAD) in the upper leg, a common cardiovascular condition that causes leg pain and increases the risk of heart attack and stroke. Recently approved by the U.S. Food and Drug Administration, ... |
| | | | 02/03/15 | FDA Grants Pre-Market Approval for Medtronic Melody® Transcatheter Pulmonary Valve| Previously Approved Under Humanitarian Device Exemption (HDE), Melody Valve Shows Safety and Effectiveness in Patients with Congenital Heart Disease DUBLIN and MINNEAPOLIS - February 3, 2015 - Medtronic plc (NYSE: MDT), today announced that its Melody® Transcatheter Pulmonary Valve (TPV) received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA) based on strong clinical evidence from three clinical studies demonstrating the valve's effectiveness in delaying ope... |
| | | | 02/03/15 | Medtronic Initiates Trial Evaluating Cryoballoon for Early Persistent AF| Enrollments Underway in France and Germany DUBLIN and MINNEAPOLIS - Feb. 3, 2015 - Medtronic plc (NYSE: MDT) today announced the initiation of the Cryo4 Persistent AF (Cryoballoon Ablation for Early Persistent Atrial Fibrillation) clinical trial. The trial will evaluate the 12-month clinical outcomes of cryoballoon ablation for isolating the pulmonary veins, without additional ablation strategies, using the Medtronic Arctic Front AdvanceTM Cryoballoon system to treat patients with early persist... |
| | | | 02/02/15 | Cardiocom, Medtronic's Patient Monitoring Services Business, Announces Partnerships with Home Health Care Companies| With New LHC Group Service Agreement, Medtronic Now Serves Four of the Five Largest Home Health Care Companies in the United States DUBLIN and MINNEAPOLIS - Feb. 2, 2015 - Medtronic plc (NYSE: MDT) announced today a partnership agreement between its Cardiocom business and LHC Group (NASDAQ: LHCG), a U.S. provider of home health, hospice and comprehensive post-acute healthcare services, to provide integrated clinical telehealth services and medical technology to their patients. This agreement ... |
| | | | 02/02/15 | Medtronic Expands Access to the Next Generation CoreValve Evolut R System with New Valve Sizes| CE Mark Approval Received for New 26 mm and 29 mm Valves MINNEAPOLIS - February 2, 2015 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européene) Mark for the 26 mm and 29 mm sizes of the CoreValve® Evolut(TM) R System, a next generation self-expanding valve that advances performance and deliverability during transcatheter aortic valve implantation (TAVI), while providing the option to recapture (re-sheath the valve back into the catheter) and reposition (move the valve to a new pos... |
| | | | 01/29/15 | Studies Show Benefits of Medtronic SmartShock(TM) Technology and Physician Reports in Protecting Patients from Inappropriate Shocks| New Results from PainFree SST, Shock-Less Studies, Involving Nearly 7,000 Patients, Published in HeartRhythm DUBLIN and MINNEAPOLIS - Jan. 29, 2015 - Medtronic plc (NYSE: MDT) today announced new results from the PainFree SST and Shock-Less clinical studies published in the journal HeartRhythm. The data show that treating patients with Medtronic implantable cardiac devices equipped with SmartShockTM Technology, and that providing clinicians with proactive reports, help physicians deliver lifesa... |
| | | | 01/28/15 | Medtronic Study Finds CoreValve® System Benefits Aortic Stenosis Patients with Prior Coronary Bypass Surgery| Analysis is First to Show Significant Advantages for Transcatheter Aortic Valve in Patients with Prior CABG DUBLIN and SAN DIEGO - January 28, 2015 - Medtronic plc (NYSE: MDT) revealed new one-year clinical data showing that transcatheter aortic valve replacement (TAVR) with the self-expanding CoreValve® System offers advantages in survival and safety compared to surgical aortic valve replacement (SAVR) in high risk aortic stenosis patients who have previously undergone coronary artery bypass ... |
| | | | 01/26/15 | Medtronic Completes Acquisition of Covidien| DUBLIN, Ireland - January 26, 2015 - Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, announced today that it has successfully completed the previously announced acquisition of Covidien plc (NYSE: COV). Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc. Shares of Medtronic plc are expected to begin trading on the New York Stock Exchange (NYSE) under the symbol "MDT" on Tuesday, J... |
| | | | 01/26/15 | Medtronic's Pending Acquisition of Covidien Approved by Irish High Court| Transaction Anticipated to Close on January 26, 2015 MINNEAPOLIS AND DUBLIN, Ireland - January 26, 2015 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the Irish High Court has sanctioned the Covidien scheme of arrangement pursuant to which Medtronic will acquire Covidien under a new holding company incorporated in Ireland to be named Medtronic plc. With the Court's approval of the scheme of arrangement, Medtronic and Covidien anticipate that the transaction, wh... |
| | | | 01/23/15 | Medtronic Introduces Enhanced Therapy to Treat Debilitating Symptoms of Serious Stomach Disorder| FDA-Approved System May Provide Long-Term Symptom Relief for Patients Suffering from Gastroparesis MINNEAPOLIS - January 23, 2015 -Medtronic, Inc. (NYSE: MDT) today announced it has received United States Food and Drug Administration (FDA) approval, under a humanitarian device exemption* (HDE),for the Medtronic Enterra® II System. The system is used to treat chronic, intractable (drug-refractory) nausea and vomiting associated with gastroparesis of diabetic or unknown origin when more conserva... |
| | | | 01/22/15 | Covidien Reports First-Quarter 2015 Results| First-quarter net sales up 2% (up 6%, excluding foreign exchange
rate movement)
First-quarter diluted GAAP earnings per share were $1.12; excluding
specified items, adjusted diluted earnings per share were $1.11
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 22, 2015--
Covidien
plc (NYSE: COV) today announced financial results for the first quarter
of fiscal 2015. First-quarter net sales of $2.69 billion increased 2%
... |
| | | | 01/21/15 | Medtronic Launches MiniMed 640G System, Breakthrough in Artificial Pancreas Technology, Outside the U.S.| New SmartGuard(TM) Technology Helps People with Diabetes Manage the Challenges of Hypoglycemia MINNEAPOLIS - January 21, 2015 - Medtronic, Inc. (NYSE:MDT) today announced the start of the global launch of the MiniMed(TM) 640G System, the next breakthrough toward an artificial pancreas. With the introduction of Medtronic's exclusive SmartGuard(TM) technology, MiniMed 640G is designed to help people with diabetes achieve better glucose control through advanced protection from hypoglycemia.... |
| | | | 01/16/15 | Medtronic Awards $150,000 Locally in Health Access Grants| Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved SANTA ANA, CALIF. - Jan. 16, 2015 - The Lestonnac Free Clinic and CHOC Children's Foundation each received a two-year Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare in Orange County. Each organization was nominated by a team of Medtronic employees working at the Medtronic Orange County site in San... |
| | | | 01/13/15 | HeartWare International Announces Preliminary Fourth Quarter 2014 Revenues| Fourth Quarter 2014 Revenues Approximately $73 Million; up 38% from Q4 in 2013
2014 Preliminary Revenues Approximately $278 Million; 34% increase from 2013
FRAMINGHAM, Mass., Jan. 13, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects revenues for the fourth quarter of 2014 will be approximate... |
| | | | 01/13/15 | HeartWare Begins HVAD® LATERAL Study, A Clinical Trial Of Advanced Heart Failure Patients Implanted Via Less-Invasive Thoracotomy Technique| FRAMINGHAM, Mass., Jan. 13, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the first patient implant in the HVAD® LATERAL Study, a U.S. Investigational Device Exemption (IDE) clinical trial in which the HeartWare® Ventricular Assist System, featuring the HVAD® Pump, is implanted through a less-invasive thoracotom... |
| | | | 01/12/15 | Medtronic Highlights Growth Opportunities at J.P. Morgan Healthcare Conference| SAN FRANCISCO -- Jan. 12, 2015 -- Chairman and CEO Omar Ishrak discussed the future of Medtronic, Inc. (NYSE: MDT) during a presentation to investors at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco today. The presentation outlined the company's continued focus on creating long-term value in healthcare through its three key strategies of therapy innovation, globalization and economic value. The pending acquisition of Covidien was also highlighted, which is expected to close... |
| | | | 01/12/15 | Medtronic Awards $150,000 Locally in Health Access Grants| Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved Goleta, CA - January 12, 2015 - Santa Barbara Neighborhood Clinics, Direct Relief and Jodi House Brain Injury Support Center each received a two-year $50,000 Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare. Each was nominated by a team of Medtronic Neurosurgery employees working in Goleta, CA. The... |
| | | | 01/08/15 | Medtronic-Sponsored European Clinical Trial to Evaluate Cryoballoon Ablation as First-Line Treatment for Patients with Symptomatic Paroxysmal Atrial Fibrillation| MINNEAPOLIS - Jan. 8, 2015 - Medtronic, Inc., (NYSE:MDT) today announced the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Arctic Front Advance(TM) cryoballoon as a first-line treatment for atrial fibrillation (AF) patients. While medication is currently considered first-line treatment for AF, clinical research indicates that half of all patients with symptomatic disease do not respond to drug therapy1; earlier ablation may improve tre... |
| | | | 01/07/15 | New Clinical Trial Will Evaluate Antibacterial Envelope in Cardiac Implantable Electronic Device Patients at Risk for Major Infections| Medtronic Announces First Patient Enrollment in the WRAP Infection Clinical Trial MINNEAPOLIS - Jan. 7, 2015 - Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in the WRAP Infection Clinical Trial, which will evaluate the effectiveness of the TYRX(TM) Absorbable Antibacterial Envelope in reducing major infections in patients with cardiac implantable electronic devices (CIEDs) at risk for infection. The global clinical trial also will assess healthcare costs related to t... |
| | | | 01/06/15 | Medtronic Shareholders Approve Proposals Related to Medtronic's Acquisition of Covidien| MINNEAPOLIS - Jan. 6, 2015 - Medtronic, Inc. (NYSE: MDT) announced that all proposals related to Medtronic's acquisition of Covidien were approved by Medtronic's shareholders today. Based on preliminary vote results, the proposal to adopt the transaction agreement and approve the merger was approved by shareholders owning approximately 95.66 percent of the shares voted at the meeting and approximately 75.18 percent of the outstanding Medtronic shares as of the record date. The final vote resu... |
| | | | 01/06/15 | Announcement under Irish Takeover Rules -- Results of Covidien plc's Shareholder Meetings| This Announcement is Being Made Solely to Comply with the
Requirements of the Irish Takeover Rules. the Information Set out Herein
Concerning the Results of Covidien plc's Shareholder Meetings on January
6, 2015 Will Also Be Set out in Covidien plc’s Form 8-K to Be Filed on
January 6, 2015
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 6, 2015--
On January 6, 2015, Covidien plc, a public limited company organized
under the laws of Ireland, held a spec... |
| | | | 01/05/15 | Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference| MINNEAPOLIS - Jan 5, 2015 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 33rd annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, in San Francisco. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about Medtronic beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 12, 2015, by clicking on the Investo... |
| | | | 01/05/15 | Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg | Pivotal Study Shows New Medical Device Provides Exceptional Clinical Outcomes and Reduces Need for Costly Repeat Procedures MINNEAPOLIS -- Jan. 5, 2015 -- Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's IN.PACT Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) in the upper leg, a serious and common cardiovascular condition that causes pain in the legs and is known to be a... |
| | | | 01/02/15 | HeartWare Presentation At The J.P. Morgan 33rd Annual Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Jan. 2, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 11:00 a.m. EST (8:00 a.m. PST) on Tuesday, January 13, 2015. The conference is being held January 12-15 at The Westin St. Francis in San... |
| | |
|
